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Summary 
Crosstalk between different types of posttranslational modifications particularly the 
multiple connections between phosphorylation and ubiquitination, is an emerging 
theme in eukaryotic biology. The premise of the present work is a step towards 
understanding structural and mechanistic basis of one such crosstalk, wherein a novel 
E3 ubiquitin ligase Hakai binds its target molecules, such as E-cadherin in a 
phosphotyrosine (pTyr) dependent manner leading to their ubiquitination and 
subsequent physiological outcomes. In this study, we focus on the pTyr-binding 
domain of Hakai, as it is the main functional domain that recognizes the pTyr motifs 
of the target proteins and act as a link for the crosstalk between the phosphorylation 
and ubiquitination machineries.  
 
Chapter I provides a general introduction about two important posttranslational 
modification machineries, viz. tyrosine phosphorylation and ubiquitination, and the 
different elements that play central roles to mediate these posttranslational 
modification processes. Besides, we elaborate the novel crosstalk between 
phosphorylation and ubiquitination with specific examples of E3 ubiquitin ligases like 
c-Cbl and Hakai, which contains pTyr-binding domain, that mediate the crosstalk. 
Our analysis based on the sequence and knowledge gained from our previous studies 
and existing literature suggest the presence of a novel pTyr-binding domain in Hakai.  
 
Chapter II describes the structural and functional characterization of the novel pTyr-
binding domain of Hakai. Phosphotyrosine-binding domains, typified by the SH2 and 
PTB domains, are critical upstream components of signal transduction pathways. The 
 xi 
E3 ubiquitin ligase Hakai targets tyrosine phosphorylated E-cadherin via an 
uncharacterized domain. In this study, the crystal structure of Hakai (aa 106-206) 
revealed that it forms an atypical, zinc-coordinated homodimer by utilizing residues 
from the phosphotyrosine-binding domain of two Hakai monomers. Hakai 
dimerization allows the formation of a pTyr-binding pocket that recognizes specific 
phosphorylated tyrosines and flanking acidic amino acids of Src substrates, such as E-
cadherin, cortactin and DOK1. NMR and mutational analysis identified the Hakai 
residues required for target binding within the binding pocket, now named the HYB 
domain. ZNF645 also possesses a HYB domain but demonstrates different target 
specificities. The HYB domain is structurally different from other phosphotyrosine-
binding domains and is a potential drug target due to its novel structural features.  
 
Chapter III describes the characterization of a C-terminal deletion mutant of HYB 
domain (HYBΔC) that exists as a monomer in solution. The NMR structure of HYBΔC 
reveals that the presence of a C2H2-like zinc figure in the C-terminal domain of 
HYBΔC instead of the atypical zinc-coordination, results in a dramatic change in the 
structure of HYBΔC compared to the HYB domain, and leads to a monomeric 
conformation. A study on the pTyr-binding property of HYBΔC through isothermal 
titration calorimetry suggested that the pTyr ligand induces dimerization of HYBΔC. 
The ligand-induced dimerization of HYBΔC is further validated through additional 
solution studies. These observations suggest that dimerization is absolutely necessary 
for the pTyr-binding property of Hakai. 
 
 The overall conclusions and the future directions are provided in Chapter IV.	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 2 
1.1 Cell Signalling 	  
In order to perform its normal physiological functions, cells must sense and correctly 
respond to the signals from their surrounding environment. Any error in sensing and 
responding to these signals manifests as a disease, such as cancer, neuro-degenerative 
disorders, auto-immunity and metabolic disorders (Anastas and Moon, 2013; 
Couvineau and Laburthe, 2012; Eijkelenboom and Burgering, 2013; Ma and Malynn, 
2012) . Extracellular signals that a cell responds may come in various forms, 
including proteins, peptides, carbohydrates, lipids and inorganic ions. These are 
recognized by the appropriate cell-membrane receptors, and the ‘message’ is passed 
from the membrane to its target, by means of intermediaries in a signaling cascade. In 
the nucleus, gene expression changes occur in response to the signals received, 
resulting in a physiological outcome. This process is referred to as cell signalling.  
 
In order to ensure that the correct signal is being propagated through the cell, the 
signaling process is both finely tuned and highly regulated. In this context, post-
translational modifications (PTMs) have evolved as the eukaryotic cell’s most 
important regulatory mechanism in cell signalling to regulate intracellular protein 
networks in response to external or internal cues (Deribe et al., 2010). Site-specific 
modification of proteins by PTMs such as phosphorylation and ubiquitination are 
involved in virtually all signaling pathways that orchestrate fundamental cellular 
processes including cell cycle progression, apoptosis, the DNA damage response, 
autophagy, and metabolism (Deribe et al., 2010). 	  	  	  
 3 
1.2 Phosphotyrosine signalling 	  
During the course of evolution, phosphorylation has emerged as one of the most 
prominent types of post-translational modification (PTM) (Hunter, 2012). Protein 
phosphorylation predominantly occurs on the hydroxyamino acids serine, threonine 
and tyrosine, and also infrequently on histidines and cysteines (Cozzone, 1988), as 
well as on lysines and arginines (Ciesla et al., 2011). It has been estimated that over 
30% of cellular proteins are phosphorylated, representing the human 
phosphoproteome (Ptacek and Snyder, 2006). Although tyrosine phosphorylation 
accounts for less than 1% of the phosphoproteome, it plays a disproportionately major 
role in disease as nearly 50% of the 90 human tyrosine kinases are implicated in 
cancer (Del Rosario and White, 2010). In the 30 years since its discovery, tyrosine 
phosphorylation has been established as a fundamentally important mechanism of 
signal transduction and regulation in all eukaryotic cells, governing many processes, 
including cell proliferation, cell cycle progression, metabolic homeostasis, 
transcriptional activation, neural transmission, differentiation and development, and 
aging (Hunter, 2009). 
 
Signal transduction via tyrosine phosphorylation, or what is known as the 
phosphotyrosine (pTyr) signalling, is mediated by an essential triad of signalling 
molecules: (1) the protein-tyrosine kinases (PTKs) that add a phosphate onto substrate 
tyrosines (conceptually these may be perceived as the ‘writers’); (2) the protein-
tyrosine phosphatases (PTPs) that remove or dephosphorylate substrates (the 
‘erasers’); and (3) the modular protein interaction domains that recognize the 
phosphorylated ligand (the ‘readers’) and hence recruit the proteins containing these 
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Figure 1.1 The Writer, Reader, Eraser pTyr Toolkit. In pTyr signaling, the tyrosine 
kinase (TyrK), pTyr Binding , and phosphotyrosine phosphatase (PTP) domains form 
a highly interdependent signaling platform. This platform serves as the writer, reader, 
and eraser modules, respectively, for processing pTyr marks. This figure is adapted 
from (Lim and Pawson, 2010), with permission from Elsevier.” 
  
Protein tyrosine kinases (PTKs) catalyze the transfer of the γ phosphate of ATP to 
tyrosine residues on protein substrates and create binding sites for the recruitment of 
downstream signaling proteins (Liu and Nash, 2012). Two classes of PTKs are 
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present in cells: the receptor Tyrosine Kinases (RTKs) and the non-receptor Tyrosine 
Kinases (NRTKs). RTKs consist of an extracellular portion that binds polypeptide 
ligands, a trans-membrane helix, and a cytoplasmic portion that possesses tyrosine 
kinase catalytic activity. NRTKs, on the other hand, lack receptor-like features such 
as extracellular ligand-binding domain and trans-membrane-spanning region, and 
mostly remains localized in the cytoplasm. In addition to a tyrosine kinase domain, 
NRTKs possess domains that mediate protein-protein, protein-lipid, and protein-DNA 
interactions (Hu and Hubbard, 2005).  
 
Protein tyrosine phosphatases (PTPs) counteract PTKs by removing phosphate 
moieties on target proteins. Together, PTPs and PTKs govern the timing, localization 
and longevity of phosphorylation events.  
 
PTKs and PTPs commonly have somewhat limited substrate specificity and thus have 
limited deterministic control over downstream events (Liu and Nash, 2012). 
Specificity in pTyr signalling is thus largely determined by pTyr binding domains that 
recognize specific tyrosine phosphorylated motifs created by PTKs and act to nucleate 
complex formation to propagate signalling. These mainly include the Src Homology 2 
(SH2) and Phospho-Tyrosine Binding (PTB) domains, which have the capability to 
recognize specific pTyr containing motifs (Forman-Kay and Pawson, 1999; Pawson 
and Nash, 2003; Yaffe, 2002). The human genome encodes roughly 90 PTKs, 107 
PTPs, 54 PTB domain-containing proteins (only about one-fifth of PTB domains can 
bind pTyr) and 111 SH2-domain-containing proteins (Liu and Nash, 2012), which 
together create a complex network of regulators that constitute pTyr-signalling 
circuitry (Figure 1.2).   
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Figure 1.2 The phosphotyrosine signalling circuitry in human. The number of writers 
(protein-tyrosine kinases, PTKs), erasers (protein-tyrosine phosphatases, PTP) and 
readers (Src homology 2, SH2; phosphotyrosine-binding domain, PTB) in humans. 
PTB (green) and SH2 (light blue) domain both contain a pTyr binding pocket (yellow 
circle), yet specificity is determined by a secondary binding site adjacent to the pTyr 
binding pocket that recognize sequences surrounding the pTyr. This figure is adapted 
from (Liu and Nash, 2012).  
 
1.3 The Src kinase and its substrates 
 
Src Kinase is a non-receptor Tyrosine Kinase and holds a remarkable historical 
significance for being the first Tyrosine Kinase to be discovered (Courtneidge, 2002; 
Martin, 2001). Src protein tyrosine kinases are 52-62 kDa proteins composed of five 
distinct functional domains: a unique domain, SH3, SH2, SH1 and a C-terminal 
regulatory region (Figure 1.3) (Boggon and Eck, 2004). The N-terminal region 
contains the myristylation signals that guide the Src molecule to the cell membrane 
while the unique domain involves in specific interaction with particular receptors and 






Figure 1.3 The domain structure of Src family kinases. The Src kinase architecture 
consists of four domains: the unique region, which varies among family members, 
followed by the SH3, SH2, and tyrosine kinase domains. By convention, amino-acid 
residues are numbered as in chicken Src. This figure is adapted from (Boggon and 
Eck, 2004), with permission from Macmillan Publishers Ltd.  
 
There are nine Src Kinases in the human genome. These proteins are all closely 
related to each other, and share the same regulatory mechanism. The prototype 
member of the Src family protein tyrosine kinases was originally identified as the 
transforming protein (v-Src) of the oncogenic retrovirus, Rous sarcoma virus, RSV 
(Brugge et al., 1977; Purchio et al., 1978). Viral v-Src is a mutated and activated 
version of a normal cellular protein (c-Src). V-Src always exists in opened, active 
conformation, whereas c-Src is flexible and normally inactive (Figure 1.4) (reviewed 













Figure 1.4 Schematic representation of Src in the inactive (left) and the active (right) 
states. The left panel represents the inactive conformation of Src, in which Tyr530 
interacts with the SH2 domain, positioning the SH3 domain to interact with the linker 
between the SH2 and catalytic domains. The right panel represents the open or active 
conformation. This figure is adapted from (Kim et al., 2009), with permission from 
Macmillan Publishers Ltd. 
  
Src participates in the maintenance of normal cell homeostasis and in a vast range of 
physiological functions including cell proliferation and survival, regulation of the 
cytoskeleton, cell shape control, maintenance of normal intercellular contacts, cell–
matrix adhesion dynamics, motility, and migration (Thomas and Brugge, 1997; 
Yeatman, 2004).  
 
Src targets numerous protein substrates by creating specific pTyr sites in them to 
mediate the downstream signaling cascades. A recent proteomic study (Luo et al., 
2008) revealed that Scr Kinases create more than 560 distinct pTyr sites on 374 
protein substrates involved signaling, adhesion and cytoskeletal regulation. Activation 
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of Src is critically involved in carcinoma cell migration and metastasis (Sakamoto et 
al., 2001) (Figure 1.5). Some of the important Src substrates that are of interest in the 
present work include E-cadherin, Cortactin and DOK1; and are briefly discussed in 
the following sections. 
 
 
Figure 1.5 Effects of c-SRC on tumour-cell behaviour. c-SRC exerts its effects on 
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tumour-cell behavior through a range of mechanisms mediated by interactions with 
various substrates and binding partners. A selection of these mechanisms is illustrated 
here. Motility and invasiveness depend on the loss of cell–cell adhesion mediated by 
E-cadherin. c-SRC promotes this by stimulating the ubiquitylation of E-cadherin, 
leading to its endocytosis. Turnover of focal adhesions is also required for motility 
and invasiveness, and c-SRC promotes this in various ways. Several of these 
mechanisms are mediated by the binding and activation of FAK, which 
phosphorylates substrates such as paxillin, CAS and p190 RHOGAP to bring about 
changes in the cytoskeleton that lead to focal-adhesion disruption. c-SRC also brings 
about similar changes independently of FAK through its interactions with 
cytoskeleton-associated proteins such as p120 catenin (p120ctn) and cortactin. 
Phosphorylation of RRAS by c-SRC inhibits integrin function, which also leads to 
focal-adhesion turnover. c-SRC activity also leads to changes in the expression of 
several genes that contribute to tumour progression. Activation of FAK stimulates the 
c-JUN amino-terminal kinase (JNK) signalling pathway, ultimately leading to 
increased expression of the matrix metalloproteinases MMP2 and MMP9; c-SRC also 
induces the expression of various tissue inhibitors of metalloproteinases (TIMPs). 
MMPs promote the breakdown of the extracellular matrix (ECM) that is required for 
tumour invasion of surrounding tissues. Signal transducer and activator of 
transcription 3 (STAT3) activation by c-SRC leads to increased expression of 
vascular endothelial growth factor (VEGF), a signalling molecule that promotes 
tumour angiogenesis. This figure is adapted from (Yeatman, 2004) with permission 
from Macmillan Publishers Ltd. 
 
1.3.1 Src substrate-E-cadherin 	  
E-cadherin is a transmembrane cell surface molecule that has a key function in 
epithelial cell adhesion. (Ishiyama et al., 2010; Pece and Gutkind, 2002). It consists of 
the extracellular cadherin domains 1–5 (EC1–5), the transmembrane region (T) and 
the cytoplasmic tail, which contains the juxtamembrane domain (JMD) and catenin-
binding domain (CBD) (Figure 1.6). E-cadherins mediate cell adhesion by 
participating in the formation of adherens junctions through calcium- dependent 
homophilic interactions of their extracellular domains, and their cytoplasmic tail is 
linked to the actin cytoskeleton through p120-catenin, β-catenin and α- catenin. 
(Figure 1.7). β-catenin interacts with the CBD and functionally links cadherins with 
the actin cytoskeleton through α-catenin (Yamada et al., 2005), while p120-catenin is 
responsible for stabilizing cadherin-catenin complexes at the cell surface by 
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interacting with the JMD (Figure 1.6 and Figure 1.7) (Davis et al., 2003; Ireton et al., 
2002; Lampugnani et al., 1997; Thoreson et al., 2000; Xiao et al., 2003).  
 
The loss of E-cadherin is a major hallmark of tumor malignancy (Hanahan and 
Weinberg, 2000). Src plays a major role in disruption of adherens junctions by 
suppressing E-cadherin localization and function at these crucial contact points by 
inducing the tyrosine phosphorylation and endocytosis of E-cadherin (Figure 1.7) 
(Pece and Gutkind, 2002). Therefore, activated c-SRC promotes the release of cells 
from each other resulting in the conversion of epithelial cells to a more migratory 
mesenchymal-like phenotype, and is linked to cancer cell spread (Figure 1.8) 
(Avizienyte and Frame, 2005; Frame, 2004). 
 
 
Figure 1.6 Schematic representation of E-cadherin. E-cadherin consists of the 
extracellular cadherin domains 1–5 (EC1–5), the transmembrane region (T) and the 
cytoplasmic tail, which contains the JMD and CBD. Sequence alignment of mEcad, 
mouse E-cadherin and hEcad, human E-cadherin is shown. Arrows show the Src 
mediated tyrosine phosphorylation sites of E-cadherin. This figure is adapted from 












Figure 1.7 Regulation of E-cadherin by Src. The cadherin-catenin complex consists 
of E-cadherin (Ecad), p120, β-catenin (βcat), and α-catenin (αcat). p120 associates 
with the cadherin JMD, which contains the endocytic LL motif (L), tyrosine-
phosphorylation sites (Y), and triple glycine motif (G). Src phosphorylate key 
tyrosine residues in E-cadherin, thereby promoting their internalization by 




Figure 1.8 Src induces breakdown of tissue architecture. Elevated Src activity results 
in suppression of cell–cell adhesion. Epithelial cells that are held together by 
intercellular contacts (bottom-left), and shown for cells from the KM12C colon 
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cancer cell series (visualized by immunofluorescence) (top-left), become dispersed as 
a consequence of expression of Src (bottom-right), shown for KM12C cells (top-
right). E-cadherin-dependent cell-cell contacts are lost as a result of oncogenic Src, 
resulting in the ‘adhesion switch’ phenotype associated with acquisition of a more 
mesenchymal-like morphology as shown. This figure is adapted with permission from 
(Frame, 2004). 
 
1.3.2 Src substrate-Cortactin 	  
Cortactin is an actin-binding protein and a central regulator of the actin 
polymerization and cell migration. Cortactin was first identified as one of the major 
substrates for Src kinase (Wu et al., 1991) (Figure 1.9). Src affects these functions by 
directly phosphorylating cortactin at the leading edge where cortactin associates with 
and activates Arp2/3, the protein complex required to initiate actin filament 
polymerization and branching (Abram and Courtneidge, 2000; Rothschild et al., 
2006). Cortactin is frequently overexpressed in malignant tumors and there is a direct 
correlation between Src mediated phosphorylation of cortactin and enhanced cell 
migration and metastasis (Boyer et al., 2002; Rothschild et al., 2006).  
 
Figure 1.9 Schematic representation of the structural domains of cortactin. The N-
terminal acidic (NTA) domain can directly activate the Arp2/3 complex. The F-actin 
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binding domain is required for Arp2/3 activation and for the localization of  cortactin 
at the cortical actin cytoskeleton. The proline-rich region contains serine and tyrosine 
phosphorylation sites and is thought to act as a molecular hinge that  determines the 
conformation of cortactin. The SH3 domain interacts with several proteins involved in 
actin polymerization, cell–cell adhesion and membrane  dynamics. Different signal 
transduction cascades regulate cortactin function via phosphorylation of specific 
serine and tyrosine residues by Pak/Erk or Src kinases, respectively. Amino-acid 
residues are numbered as in mouse Cortactin. This figure is adapted from (Selbach 
and Backert, 2005), with permission from Elsevier. 
  
1.3.3 Src substrate- DOK1 	  
DOK1 belongs to a family of adaptor proteins and serve as a scaffold protein for the 
recruitment of downstream signaling components. Tyrosine phosphorylation induced 
by Src Kinase or c-Abl are reported to be required for Dok1 functions (Lee et al., 
2004; Liang et al., 2002; Rao and Mufson, 1995; Woodring et al., 2004; Zhao et al., 
2001). 
DOK1 is characterized by a Pleckstrin Homology domain (PH) that allows anchorage 
to the membrane, a PTB domain that is involved in protein-protein interactions, and a 
C-terminal region rich in tyrosine and serine residues (Figure 1.10) (Niu et al., 2006). 
Tyrosine phosphorylation by Src modulates interactions with several SH2-containing 
signaling molecules such as RasGAP, Nck, and the X-linked lymphoproliferative 
syndrome gene product SH2D1A (Niu et al., 2006).  
 
DOK1 has emerged as a key negative regulator downstream of several receptor and 
non-receptor tyrosine kinase cascades. DOK1 down-regulates cell proliferation and 
lymphocyte signaling, inhibits mitogen-activated protein (MAP) kinase activity, and 
mediates activin-induced apoptosis (Kato et al., 2002; Nemorin et al., 2001; Tamir et 
al., 2000; Yamakawa et al., 2002). In addition to its inhibitory effects on various 
cellular functions, it plays positive roles in cell adhesion, cell spreading, and cell 
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migration (Niu et al., 2006). 
 
Figure 1.10 Domain architecture of DOK1. Amino-acid residues are numbered as in 
mouse DOK1. Tyrosine residues phosphorylated by v-Src are shown. 
 
1.4 Phosphotyrosine (pTyr) binding domains in cell signalling 	  
1.4.1 Major pTyr binding domains: SH2 and PTB domains 	  
Phosphotyrosine binding domains, typified by the SH2 and PTB domains, recognize 
phosphotyrosine-containing motifs in a wide variety of target molecules in a sequence 
specific manner and enable the information flow from the cell surface to different 
cellular compartments to regulate the cell cycle, cell shape and movement, cell 
proliferation, and differentiation (Yaffe, 2002).  
 
The SH2 domain was discovered as the first modular signalling domain that can bind 
to its ligands in a phosphorylation-dependent manner. (DeClue et al., 1987; Sadowski 
et al., 1986). At the time of discovery, 26 SH2 domain-containing proteins were 
predicted, but over time, more SH2 domains have been discovered and presently 
around 111 SH2 domains have been identified in the human genome (Liu et al., 2012; 
Liu and Nash, 2012). The SH2 domain is thus considered as the principal and most 
predominant pTyr-binding domain (Filippakopoulos et al., 2009; Forman-Kay and 
Pawson, 1999; Liu et al., 2012; Liu et al., 2006; Pawson and Nash, 2003; Songyang et 
al., 1993; Yaffe, 2002). The binding specificity of the SH2 domain is generally 
conferred by the sequences flanking the C-terminus of the pTyr. PTB domain was 
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discovered as a second conserved phosphotyrosine-binding module after the SH2 
domain, identified in the adaptor protein SHC and insulin receptor substrate-1 (IRS-1) 
(Kavanaugh and Williams, 1994). They have since been found in various signalling 
molecules and currently around 54 PTB domain-containing proteins have been 
identified in human genome (Liu and Nash, 2012). The binding specificity of the PTB 
domain is generally conferred by the sequences flanking the N-terminus of the pTyr. 
The different mode of recognition of the phospho-peptide motif from the substrate by 
SH2 and PTB domains is shown in Figure 1.11. Furthermore, unlike SH2 domains 
which can bind only pTyr-motifs, the PTB domain also recognizes non-pTyr motifs, 
as evident from the observation that only about one-fifth of the 54 known PTB 
domains can bind pTyr (Farooq and Zhou, 2004; Forman-Kay and Pawson, 1999; Liu 
and Nash, 2012; Pawson and Nash, 2003; Smith et al., 2006; Yaffe, 2002). 
 
 
Figure 1.11 Different modes of peptide recognition by SH2 and PTB domains. 
Ribbons representations are shown on the left for the Src  SH2 domain [PDB code 
1SPS] and on the right for IRS-1 [PDB code 1IRS]. Superimposed in each case are 
multiple different ligands, to show how they bind with respect to the SH2 or PTB 
domain fold. For SH2 domains, eight different SH2/phosphopeptide  complex 
structures were overlaid. Peptide coordinates from each of the overlaid structures 
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were superimposed on a representation of the Src SH2  domain. For PTB domains, 
the six PTB domain/peptide complex structures were overlaid. Peptide coordinates 
were superimposed on a representation of the  IRS-1 PTB domain. The SH2 domain 
structures used were Src, Lck [PDB code 1LCJ], C-terminal p85 SH2 domain [PDB  
code 1H9O], C-terminal PLC-γ1 SH2 domain [PDB code 2PLD], Fyn [PDB code 
1AOT], Grb2 [PDB code 1TZE], SAP [PDB code 1D4W], N-terminal SH2 domain 
from Syp [PDB code 1AYA]. The PTB domain structures used  were IRS-1 [PDB 
code 1IRS], Shc [PDB code 1SHC], X11 [PDB code 1X11], Numb [PDB code 
1DDM], talin [PDB code 1MIZ], and radixin [PDB code 1J19]. This figure is adapted 
from (Schlessinger and Lemmon, 2003).  
 
1.4.2 Idiosyncratic pTyr binding domains 	  
SH2 and PTB domains are described as the two major pTyr binding domains 
(Forman-Kay and Pawson, 1999; Pawson and Nash, 2003; Yaffe, 2002). In addition 
to these, at least two more pTyr binding domains have been identified. These include 
the C2 domain of PKCδ (Benes et al., 2005) and the M2 isoform of Pyruvate Kinase 
(Christofk et al., 2008). However, both appear to be idiosyncratic properties of this 
particular C2 family member and Pyruvate kinase isoform respectively, as in normal 
situations, C2 domains are known to bind phospholipids (Benes et al., 2005) and 
Pyruvate Kinases catalyze the conversion of phosphoenolpyruvate to pyruvate 
(Christofk et al., 2008).  
 
So far, we discussed about the various elements of pTyr mediated signalling which 
basically involve protein modification by the addition of small phosphate moieties on 
the substrate tyrosine residues and subsequent recognition of these modifications by 
the pTyr-binding domains which play central roles in creating a highly dynamic relay 
system that reads and responds to alterations in the cellular microenvironment. 
Another class of protein modification that plays a vital role in cell signalling involves 
covalent attachment of short modifier proteins such as ubiquitin and ubiquitin-like 
 18 
proteins (UBLs). This process in known as Ubiquitination and is discussed in the 
following sections. 
 
1.5 Ubiquitination 	  
Protein ubiquitination is an important post-translational modification that involves the 
covalent attachment of ubiquitin and UBLs to the target proteins. Ubiquitin is a highly 
conserved 76-amino-acid polypeptide that is covalently attached to target proteins via 
an isopeptide bond between the carboxyl-terminal glycine of ubiquitin and the           
epsilon-NH2 group of a lysine in substrate proteins. Ubiquitin conjugation can affect 
different properties of the target (Hoege et al., 2002), including the protein’s half-life, 
enzymatic activity, subcellular localization and protein–protein interactions 
(Hochstrasser, 1996; Jentsch and Pyrowolakis, 2000; Pickart, 2001; Yeh et al., 2000). 
It has emerged as a predominant cellular regulatory mechanism, with important roles 
in controlling cell division, signal transduction, embryonic development, endocytic 
trafficking and the immune response (Huang et al., 2004).  
 
Ubiquitin conjugation to a substrate involves a cascade of at least three different 
enzymatic reactions (Figure 1.12). First, ubiquitin is activated by E1, the ubiquitin-
activating enzyme, to form a high-energy thioester linkage between its C-terminal 
glycine residue and an active cysteine on the E1. Next, the thiol-linked ubiquitin is 
transiently transferred to the next enzyme in the cascade- E2, the ubiquitin-
conjugating enzyme. Finally, an E3 ubiquitin ligase either transfers the activated 
ubiquitin molecule from the E2 to a lysine residue on the substrate or facilitates the 
transfer of ubiquitin from the E2 directly to the substrate (Hershko and Ciechanover, 
1998). This series of events can also take the reverse course, through the action of 
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deubiquitinating (DUBs) enzymes, which remove ubiquitin chains from specific 
ubiquitin-protein conjugates (Wilkinson, 2000). 
 
 
Figure 1.12 Overview of the ubiquitin-conjugation pathway. Ubiquitin (green circles) 
is and attached to substrate proteins by a series of enzymes. Three types of enzyme — 
E1, E2 and E3 — carry out ubiquitin-modification reactions, including the assembly 
of polyubiquitin chains (conjugation of additional ubiquitins to a single ubiquitin to 
form a polyubiquitin chain on some proteins is indicated by the brackets in the 
image). E1s activate ubiquitin. E2s pick up the ubiquitin by transthiolation from E1 
and conjugate it to substrates. E3s then ligate the ubiquitin to the substrate (and in 
some cases, form an intermediary thioester with ubiquitin before the final transfer to 
the substrate). All eukaryotes encode multiple isozymes of E2 and E3, up to several 
dozen E2s and many hundreds of E3s. This allows the modification of many proteins 
in a highly specific manner, and such modifications are often under strict temporal 
and spatial control. This figure is adapted from (Hochstrasser, 2009), with permission 




There are many forms by which the target protein could be modified by 
ubiquitination. The various ubiquitin modifications adopt distinct conformations and 
lead to different outcomes in cells. The addition of a single ubiquitin molecule to a 
substrate is defined as mono-ubiquitination (Figure 1.13) (Hicke and Dunn, 2003). 
Alternatively, several lysine residues in the substrate can be tagged with single 
ubiquitin molecules, giving rise to multiple mono-ubiquitination, also referred to as 
multi-ubiquitination (Figure 1.13) (Haglund et al., 2003). Moreover, ubiquitin 
contains seven lysine residues, which can also be targeted by another ubiquitin in an 
iterative process, known as poly-ubiquitination, that leads to the formation of a 
ubiquitin chain attached to a single lysine of a protein substrate (Figure 1.13) 
(Hofmann and Pickart, 2001). It is now clear that different types of ubiquitin 
conjugates are involved in the regulation of different cellular processes. 
 
 
Figure 1.13 Ub modifications and their cellular functions. Attachment of a single Ub 
molecule to a single Lys (K) residue leads to protein mono-ubiquitylation (mono-Ub). 
Multiple mono-ubiquitylation (multi-Ub) results from the addition of several single 
Ub molecules to different Lys residues. These modifications are implicated in various 
nonproteolytic cellular functions, including endocytosis, endosomal sorting and DNA 
repair. Poly-ubiquitylation (poly-Ub) results from the attachment of a chain of Ub 
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molecules to one or more Lys residues. Ub chains formed via Lys48 (K48) of Ub 
target-modified proteins for proteasomal degradation. Chains linked via Lys63 (K63) 
are implicated in DNA repair and activation of protein kinases. This figure is adapted 
from (Haglund and Dikic, 2005), with permission from Macmillan Publishers Ltd. 
 
 
1.5.1 E1 and E2 enzymes 	  
The human ubiquitin pathway involves a hierarchical network that is constituted by 
two E1 enzymes, 37 E2 enzymes, over 600 E3 ligases, and thousands of targets with 
diverse biological functions (Komander, 2009; Schulman, 2011). UBA1 and UBA6 
are the two E1 enzymes present in human (Pelzer et al., 2007; Schulman and Harper, 
2009). The E1 enzymes consist of three independently- folded globular domains, each 
specifying distinct E1 activities: (1) an adenylation domain binds the ubiquitin and 
MgATP and contains the adenylation reaction active site; (2) a catalytic Cys domain 
that harbors the active site Cys that is involved in the E1~Ubiquitin thioester linkage 
and (3) a carboxyl-terminal ubiquitin-fold domain (UFD) that resembles ubiquitin that 
binds E2 (Schulman, 2011). E1 enzymes use ATP to generate a thioester bond 
between the Cys at their active site and the carboxyl terminus of ubiquitin and then 
transfers this activated ubiquitin to the Cys residue in the active site of an E2 enzyme 
(Ye and Rape, 2009). E2 enzymes act via selective protein–protein interactions with 
the E1 and E3 enzymes and connect activation to covalent modification. E2s contain a 
highly conserved ubiquitin-conjugating (UBC) domain, which accommodate the 
ATP-activated ubiquitin from the E1 enzyme via a covalently linked thioester onto its 
active-site residue. After being charged with ubiquitin, E2s engage E3s to catalyse 
substrate ubiquitylation. A single E2 can interact with several different E3s 
(Komander, 2009; Ye and Rape, 2009). Although the analysis of E2–E3 interactions 
in vitro is straightforward, determining the physiological E2–E3 pairs, especially in 
human cells, is more difficult (Ye and Rape, 2009). 
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1.5.2 E3 ubiquitin ligases 	  
E3 ligases confer specificity to ubiquitination by recognizing target substrates and 
mediating transfer of ubiquitin from an E2 ubiquitin conjugating enzyme to substrate 
(Deshaies and Joazeiro, 2009). There are three major types of E3 ligases in 
eukaryotes. These include a RING, U-box and HECT (Ardley and Robinson, 2005; 
Gao and Karin, 2005).  
 
1.5.2.1 RING E3 ligases 	  
RING (really interesting new gene) E3 Ligases are the most prominent class of 
ubiquitin-ligases with over 600 different RING ligases encoded by human genome 
(Deshaies and Joazeiro, 2009). RING domain has several cysteines and a histidine in 
its core structure comprising of 40 to 60 amino acid residues which bind two zinc 
atoms (Borden and Freemont, 1996) (Figure 1.14).  RING E3 ligases act as adaptor 
which bring an E2 bound with ubiquitin (E2∼Ub) and a substrate into sufficiently 
close proximity and promote direct transfer of ubiquitin from E2∼Ub to substrate 
(Deshaies and Joazeiro, 2009) (Figure 1.17). Members of the RING finger ubiquitin 
ligase family can function as monomers, dimers or multi-subunit complexes. 
Dimerization generally occurs through the RING finger domain or surrounding 
regions and can result in homodimers [e.g. cIAP, RNF4, SIAH, and TRAF2] (Liew et 
al., 2010; Mace et al., 2008; Park et al., 1999; Polekhina et al., 2002) or heterodimers 
[e.g. (MDM2 and MDMX), (BRCA1 and BARD1), (RING1b and BMI1)] (Metzger 
et al., 2012). For heterodimers, one RING domain (MDMX, BARD1, BMI1) often 
lacks ligase activity and might conform and/or stabilize the active E2-binding RING 
domain. Multi-subunit RING domains are exemplified by the cullin RING ligase 
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(CRL) superfamily (Petroski and Deshaies, 2005) and anaphase-promoting 
complex/cyclosome (APC/C) (Metzger et al., 2012). 
 
 
Figure 1.14 The RING finger domain. (A) Primary sequence organization of the 
RING-HC domain. The first cysteine that coordinates zinc is labeled as C1, and so on. 
H1 denotes the histidine ligand. Xn refers to the number of amino acid residues in the 
spacer regions between the zinc ligands. (B) Ribbon diagram of the three-dimensional 
crystal structure of the RING domain from c-Cbl. The zinc atoms in sites I and II are 
numbered. The termini are as marked. This figure is adapted with permission from 
(Deshaies and Joazeiro, 2009); permission conveyed through Copyright Clearance 
Center, Inc. 
 
1.5.2.2 U-box E3 ligases 	  
U-box domains are structurally related to the RING and function in mediating 
ubiquitination (Figure 1.15 and Figure 1.17). In the U-box domain, the zinc-binding 
sites are replaced by conserved charged and polar residues that engage in hydrogen-
bonding networks and that are required for maintaining structure and activity 
(Aravind and Koonin, 2000) (Figure 1.15). The human genome codes for around 7 




Figure 1.15 The structural scaffold of the RING and U-box domain. (A) Known 
structures of the indicated protein domains. (B) Model of the U-box structure 
constructed using PROMODII from the structures in (A,B) and the U-box sequence 
from UFD2. W, Trp residue conserved in RING fingers; N, amino terminus; C, 
carboxyl terminus. This figure is adapted from (Aravind and Koonin, 2000), with 
permission from Elsevier. 
 
1.5.2.3 HECT E3 ligases 	  
HECT domains are identified on the basis of their similarity to the founding member 
of the family, E6AP. HECT (homologous to E6-associated protein C-terminus) E3s 
have a direct role in catalysis during ubiquitination. In contrast to RING domains, 
which can occur at any position within a given protein, all known HECT domains are 
found at the carboxy-terminal end of their respective proteins (Wenzel and Klevit, 
2012). The HECT domain has a bilobal structure: the lobe at the amino-terminal end 
of the domain (the N-lobe) serves as the E2-binding domain, and the lobe at the 
carboxyl terminus (the C-lobe) contains the catalytic cysteine (Huang et al., 
1999)(Figure 1.16). The catalytic cysteine forms thioester with ubiquitin before it is 
transferred from E2∼Ub to the substrate. This is in sharp contrast to the RING and U-
box type E3 ligases, which transfers the ubiquitin directly from E2∼Ub to the 
substrate (Figure 1.17). Database analyses indicate that the human genome encodes 
28 different HECT proteins (Scheffner and Staub, 2007). 
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Figure 1.16 The E6AP HECT domain–UbcH7 (UbcH7 is an E2 enzyme) complex 
forms a U-shaped structure. (A and B) Orthogonal views of the overall structure of 
the complex. The E6AP HECT domain N lobe (consisting of 12 α helices and six β 
strands), C lobe (six α helices and four β strands), and the E2 enzyme, UbcH7 (four α 
helices and four β strands) are colored in green, red, and cyan, respectively. The two 
active-site loops that contain the catalytic cysteine are colored yellow. The dotted line 
indicates the open line of sight between the active-site cysteines of E6AP and UbcH7. 
This figure is adapted from (Huang et al., 1999), with permission from American 
Association for the Advancement of Science (AAAS). 
 
The mode of action of the different E3 ligases showing the mechanism of ubiquitin 
transfer from the E2∼Ub to the substrate is indicated schematically in Figure 1.17.  
 
 
Figure 1.17 Summary of classification of E3 ligases. RING type and U-box type E3 
ligases transfer the ubiquitin directly from E2∼Ub to substrate, whereas HECT type 
E3s form thiol-ester intermediates with ubiquitin and then transfers it to the substrate. 
In all the three cases, the E3 ligases engage with their substrates through their 
respective Substrate Binding Domain, denoted in the figure as SBD, and mediate the 
Ubiquitin transfer from the E2 enzyme to the substrate. 
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To this point, we discussed about two important PTMs- Tyrosine Phosphorylation and 
Ubiquitination- that play pivotal role in the regulation of cell signaling in eukaryotic 
cells. In recent findings, compelling amount of data indicates the involvement of a 
sequential series of PTMs like phosphorylation and ubiquitination in tandem in 
transmitting and regulating signaling (Deribe et al., 2010). In the following sections, 
we briefly discuss the emerging insights in the similarities and crosstalk between 
phosphorylation and ubiquitination. 
 
1.6 Similarities between ubiquitination and phosphorylation 	  	  
There are many similarities between phosphorylation and ubiquitination (Figure 
1.18). First, both are reversible forms of covalent modification: just as 
phosphorylation can be reversed by protein phosphatases, ubiquitination can be 
reversed by members of a large family of enzymes known as deubiquitinating (DUBs) 
enzymes. Second, both occur rapidly, often within minutes or seconds following 
stimulation. Third, both are highly specific and controlled by a very diverse set of 
enzymes. The human genome project reveals the presence of >30 different E2s, >500 
different E3s and >80 different Dubs (Komander, 2009). Such diversity rivals that of 
protein kinases (of which there are a total of 518 in humans) and phosphatases (a total 
of 120). Fourth, both ubiquitination and phosphorylation can be detected by 
specialized domains that bind to ubiquitin or phospho-amino acids, respectively. In an 
analogous manner as the specific sequences containing pTyr can be recognized by 
SH2 and PTB domains, ubiquitin and polyubiquitin chains can be recognized by 
several different classes of ubiquitin-binding domains present in a wide variety of 
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proteins (Ghosh and Karin, 2002). These domains include UIM (Ub-interacting 
motifs), UBA (Ub-association), CUE (Cue1-homologous), UEV (Ub E2 variant), 
PAZ (poly ubiquitin associated zinc finger) and NZF (novel zinc finger).  
 
 
Figure 1.18 Comparison of ubiquitination and phosphorylation Systems. 
Ubiquitination and phosphorylation are reversible processes. The enzymes facilitating 
and removing the modifications are indicated, and numbers in parentheses indicate 
the number of human genes encoding the respective proteins. As for protein kinases 
and phosphatases, E2 conjugating enzymes and deubiquitinases also comprise several 
pseudogenes that lack catalytic residues and are hence inactive. The roles of inactive 
deubiquitinases are currently unknown, whereas the inactive E2 enzymes Uev1a and 
MMS2 have important roles in the assembly of Lys63-linked ubiquitin chains. K, 
lysine residue; P, phosphorylation; PBD, phosphate-binding domain; S, substrate; 
S/T/Y, serine/threonine/tyrosine residue; Ub, ubiquitin; UBD, ubiquitin-binding 
domain. This figure is adapted with permission from (Komander, 2009). © the 
Biochemical Society. 
 
1.7 Crosstalk between ubiquitination and phosphorylation 	  
Crosstalk between ubiquitination and phosphorylation occurs at several levels (Figure 
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1.19). Phosphorylation can promote or inhibit ubiquitination, which in turn can lead to 
proteasomal degradation or processing or regulate intracellular trafficking of 
membrane proteins (Hunter, 2007). Phosphorylation can regulate ubiquitination of a 
protein in three main ways. First, phosphorylation positively or negatively regulates 
the activity of the E3 ligase responsible for Ub transfer. Second, phosphorylation 
promotes recognition by an E3 ligase by creating a phosphodegron. Third, 
phosphorylation can influence ubiquitination by regulating substrate/ligase interaction 
at the level of subcellular compartmentalization.  
 
 
Figure 1.19 Crosstalk between Phosphorylation and Ubiquitination. Crosstalk 
between phosphorylation and ubiquitination occurs at several levels (Figure 1). 
Phosphorylation can promote or inhibit ubiquitination, which in turn can lead to 
proteasomal degradation (polyUb, e.g., cyclin E) or processing (polyUb, e.g., Ci or 
NF-kB2/p100) or regulate intracellular trafficking of membrane proteins (monoUb, 
e.g., Ste2 and EGFR). Phosphorylation can regulate ubiquitination of a protein in 
three main ways. First, phosphorylation positively or negatively regulates the activity 
of the E3 ligase responsible for Ub transfer. Second, phosphorylation promotes 
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recognition by an E3 ligase by creating a phosphodegron. Third, phosphorylation can 
influence ubiquitination by regulating substrate/ligase interaction at the level of 
subcellular compartmentalization. This figure is adapted from (Hunter, 2007), with 
permission from Elsevier. 
 
 
1.7.1 Example of crosstalk: pTyr dependent ubiquitination by c-Cbl 	  
A classical example of the crosstalk between phosphorylation and ubiquitination is 
the phosphotyrosine dependent ubiquitination and degradation of receptor and non-
receptor tyrosine kinases by the RING E3 ligase c-Cbl (Figure 1.20).  
 
 
Figure 1.20 CBL proteins mediate ubiquitylation (Ub) and the downregulation of 
receptor tyrosine kinases (RTKs). Whether CBL proteins associated with activated 
complexes are degraded in lysosomes or proteasomes is unresolved. Here, P stands 
for phosphorylation. This figure is adapted from (Lipkowitz and Weissman, 2011), 
with permission from Macmillan Publishers Ltd. 
  
Recently, our lab has shown that c-Cbl interacts with a diverse array of RTKs and 
NRTKs in a phosphotyrosine dependent manner through a N-terminal pTyr- binding 
domain lying adjacent to the RING domain (Ng et al., 2008). Although this pTyr- 
binding domain appeared to have several hallmarks of a PTB consensus motif, the 
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crystal structure demonstrated that it structurally resembled an SH2 domain but 
required a flanking four-helix bundle (4H) and an EF-hand subdomain to accomplish 
binding (Meng et al., 1999; Ng et al., 2008). Together, these three sub-domains make 
up the tyrosine kinase-binding (TKB) domain, which is unique to Cbl proteins and 




Figure 1.21 c-Cbl and pTyr recognition. (A) Domain architecture of c-cbl [adapted 
from (Ng et al., 2008)] (B) Structure of the tyrosine kinase-binding (TKB) domain of 
Cbl bound to a ZAP-70 phosphopeptide. The Cbl TKB domain comprises three 
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structural domains: a four-helix bundle (yellow), an EF-hand Ca21-binding domain 
(green) and a divergent SH2 domain (blue). [Adapted from (Lupher et al., 1999), with 
permission from Elsevier.] 
 
1.7.2 Unique pTyr recognition mechanism of c-Cbl TKB 	  
The c-Cbl TKB domain binds its target proteins following phosphorylation of a 
central tyrosine residue in the consensus motif. Binding to the TKB domain is 
required for the subsequent conjugation of ubiquitin through the RING domain during 
the ubiquitination process (Schmidt and Dikic, 2005). The consensus binding 
sequence targeted by the TKB domain was originally identified by (Lupher et al., 
1997) as D(N/D)XpY, but was later experimentally refined as (N/D)XpY(S/T)XXP. 
This motif is common to several RTKs, such as EGFR, colony-stimulating factor 1 
receptor, ZAP-70, Src and Syk, as well as members of the Sprouty (Spry) family of 
Ras/ mitogen-activated protein kinase inhibitors (Figure 1.22). In our lab, we 
identified two additional consensus motifs that are targeted by the c-Cbl-TKB domain 
(Ng et al., 2008). The first, RA(V/I)XNQpY(S/T), is a derivation of the original 
sequence, with conserved residues extending back to the arginine at the pY-6 position 
(Figure 1.22). This sequence is conserved amongst a family of adaptor proteins based 
on the APS protein (Hu and Hubbard, 2005). The second consensus sequence was 
identified as a DpYR motif in a study investigating the binding of c-Cbl to the c-Met 
receptor (Met). This motif bears no resemblance to the previously characterized PTK-
binding motif (Peschard et al., 2004) and is conserved among the Met family 
members, Ron and Sea (Penengo et al., 2003), as well as in plexins - receptors for 
semaphorins that promote cell repulsion (Tamagnone et al., 1999)( Figure 1.22).  
 
Although the 111 currently documented SH2 domains use diverse strategies to 
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aggregate signalling complexes, there is no precedent for a given SH2 or PTB domain 
to associate with such apparently unrelated consensus binding motifs as seen with the 
TKB domain. A recent study by our lab (Ng et al., 2008) revealed the hitherto 
undiscovered common binding mechanism that effectively explains the basis of the 
unique ability of c-Cbl TKB to recognize diverse substrate motifs. By using a 
combination of structural and biochemical approaches, we demonstrated that TKB 
binding requires the formation of a unique intrapeptidyl hydrogen bond (H-bond) 
between the pTyr and the conserved asparagine (Asn) at the pY-2 position or an 
arginine (Arg) at the pY-1 position when the Asn is absent (Figure 1.23A). 
Furthermore, Met binds to the TKB domain in the reverse direction, from N to C 
terminus with the formation of an intrapeptidyl H-bond between the pTyr and the Arg 
at the pY-1 position (Figure 1.23B). This was the first description of an SH2 domain 
having the capacity to bind to proteins in two orientations. In order to gain further 
structural insights into the reverse binding mechanism of c-Cbl-TKB, our lab used a 
protein engineering approach wherein the Met peptide with the DpYR motif was 
changed to RpYD (MetRD) (Sun et al., 2011). Here, we demonstrated that the MetRD 
peptide binds with TKB with a similar binding affinity as the native Met peptide, but 
with a complete reversal in orientation. In this study, we established that the binding 
orientation is dictated by the phosphorylated tyrosine and an adjacent arginine which 
forms the intra-peptide hydrogen bonds and aligns the pTyr motif unidirectionally 
with complementary charges in the phosphotyrosine binding pocket of c-Cbl (Sun et 
al., 2011). Moreover, our lab has further contributed in understanding the pTyr 
binding mechanism of c-Cbl TKB by demonstrating that additional serine/threonine 
phosphorylation reduces binding affinity but preserves interface topography of 




Figure 1.22 Diverse pTyr motifs of c-Cbl TKB. Sequence alignment of c-Cbl-TKB 
binding sites for the PTK, APS and Met subgroups of proteins. This figure is adapted 
from (Ng et al., 2008), with permission from Macmillan Publishers Ltd. 
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Figure 1.23 Unique binding mechanism employed in c-Cbl TKB to recognize diverse 
pTyr motifs (A) Orientation of the intrapeptidyl hydrogen bond of the Spry249–61 
phosphopeptide within the binding pocket of the Cbl-TKB (B) Recognition of    
Met997–1009 phosphopeptide involves the essential intrapeptidyl hydrogen bond and 
reverse binding of c-Cbl-TKB domain. This figure is adapted from (Ng et al., 2008), 
with permission from Macmillan Publishers Ltd. 
 
 
1.8 Discovery of Hakai- a ‘c-Cbl like’ protein 	  
E-cadherins play major role in epithelial cell adhesion, through the establishment of 
calcium dependent homophilic interactions at sites of cell-to-cell contact (Fujita et al., 
2002; Pece and Gutkind, 2002). During tumor progression, disruption of cell-cell 
contacts plays a pivotal role in metastasis as well as in the dedifferentiation process 
that accompanies the malignant phenotype (Thiery and Sleeman, 2006). The most 
common malignancies in humans are carcinomas that are comprised of cells epithelial 
in origin (Guarino, 2010) and thus the loss of E-cadherin is considered as a major 
hallmark of tumor malignancy (Hanahan and Weinberg, 2000). The tyrosine kinase 
Src plays an active function in this process, as it phosphorylates tyrosine residues in 
the short intra-cytoplasmic tail of E-cadherins, thereby promoting their internalization 
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by endocytosis (Figure 1.24) (Fujita et al., 2002; Guarino, 2010; Pece and Gutkind, 
2002). In search of the underlying molecular mechanism, Fujita et al. (2002) 
identified a new molecule, named Hakai (Hakai means ‘destruction’ in Japanese), that 
binds tyrosine phosphorylated E-cadherins and mediates the internalization and 
subsequent ubiquitin-dependent degradation of E-cadherins (Figure 1.24). Pece and 
Gutkind (2002) proposed a dynamic model for the function of Hakai mediated 
ubiquitination in E-cadherin endocytosis and trafficking, in which E-cadherins are 




Figure 1.24 A model for Hakai in the dynamic regulation of E-cadherin- mediated 
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adherens junction. (a) At steady-state, E-cadherins are organized in multiprotein 
complexes in adherens junctions. (b) Activation of receptor (RTKs) and non receptor 
(NRTKs) tyrosine kinases promotes the phosphorylation of β-catenin and the 
intracytoplasmic tail of E-cadherin (P), the recruitment of Hakai in a tyrosine-
phosphoylation dependent manner, the loss of E-cadherin interaction with the actin 
cytoskeleton, and the disruption of adherens junctions. (c) E-cadherin bound to Hakai 
may initiate the activation of intracellular signalling pathways, whereas the E3-ligase 
function of Hakai mediates the transfer of ubiquitin chains to E-cadherin and β- atenin 
through the E1–E2 ubiquitination system. (d) Ubiquitinated β-catenin is degraded in 
the proteasome, but ubiquitinated E- adherin–Hakai complexes are likely internalized 
by clathrin-coated pits, which are then (e) rapidly uncoated and fuse to early 
endosomes. (f) In endosomes, depending on a balance between ubiquitination and de-
ubiquitination systems, E-cadherin may be either recycled back to the cell surface (g), 
or targeted for degradation in the lysosomal compartment (h). The possible function 
of members of the Rab family of GTPases in the intracellular trafficking of E-
cadherin is depicted. This figure is adapted form (Pece and Gutkind, 2002), with 
permission from Macmillan Publishers Ltd. 
 
 
Fujita et al. (2002) showed that Hakai functions as an E3 ubiquitin ligase that binds E-
cadherin in a tyrosine phosphorylation-dependent manner. E3 ubiquitin ligases exhibit 
distinct structural features that determine their binding specificity and their ability to 
engage the ubiquitin conjugating enzymes. The latter includes the HECT domains, the 
RING finger domains, and the recently identified U-box domain. Hakai belongs to the 
second group, as it has a RING finger domain related to that of the c-Cbl. The 
relationship with c-Cbl goes beyond this domain and its function, as Hakai also 
exhibits a phosphotyrosine-binding domain and an extended proline-rich region that 
are highly related to those of c-Cbl (Figure 1.25). Furthermore, like c-Cbl, Hakai also 
binds to its target in a phosphotyrosine dependent manner resulting in its 
ubiquitination and subsequent degradation. Due to its similarity with c-Cbl, Hakai is 
also designated as CBLL1 (c-Cbl-like protein 1). 
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Figure 1.25 Schematic diagrams of the Hakai and c-Cbl domains. There is a mild 
degree of sequence homology between Hakai and c-Cbl’s RING finger (~20%) pTyr 
binding domain (~8%) and proline-rich region (~14%); however the domains are 
ordered differently on the respective proteins. 
 
Hakai was originally identified as a key regulator of cell-cell contacts by controlling 
the fate of E-cadherin. Several lines of research over the last 10 years since the 
discovery of Hakai have delineated its emerging and crucial role in various cellular 
processes including adhesion, migration, embryogenesis, tumorigenesis and other 
diseases (Aparicio et al., 2012). A brief account of the knowledge that has been 
accumulated since Hakai discovery and its implication in human cancer and infectious 
disease is discussed in the following sections.  
 
1.9 Important biological implications of Hakai  	  
1.9.1 Hakai and Cancer 	  
There are several lines of evidences that support multiple roles of Hakai in 
tumorigenesis. For instance, Hakai is highly up-regulated in human colon and gastric 
cancers, suggesting its direct involvement in cancer (Figueroa et al., 2009). Moreover, 
Hakai reduces cell attachment to the substrate and enhances the invasion capacity in 
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epithelial MDCK cells (Rodriguez-Rigueiro et al., 2011a). Furthermore, the 
overexpression of Hakai results in the down-regulation of Paxillin- a key focal 
adhesion associated protein, leading to the loss of cell adhesion in a proteasome-
independent mechanism (Rodriguez-Rigueiro et al., 2011b). These observations 
substantiate the significant link between Hakai and cancer. 
 
Considering the important role of Hakai in tumor progression, it could be an attractive 
target for therapeutic interventions against cancer. 
 
1.9.2 Hakai and Infectious disease 	  
There are several reports that describe Hakai’s role in infectious disease. The first 
work describing Hakai in this process was by Krishnan et al. (Krishnan et al., 2008). 
By using a human genome-wide RNAi screen they identified Hakai as a protein that 
affect West Nile virus (WNV) infection. WNV belongs to the genus flavivirus, which 
constitute a significant global human health problem (Brinton, 2002). They proposed 
Hakai to be involved in the cellular internalization of WNV. They demonstrated that 
Hakai and the proteasome–ubiquitin systems are required for the cellular 
internalization of WNV (Krishnan et al., 2008). Still, the implication of Hakai during 
WNV infectious needs to be further clarified.  
 
Other important studies on Hakai in infectious disease were reported in Listeria 
monocytogenes. Upon infection, Listeria leads to a wide range of symptoms 
associated to listeriosis, such as gastroenteritis, fetoplacental, and central nervous 
system infections (Lecuit, 2005). Internalization of L. monocytogenes mainly occurs 
via two bacterial surface proteins: internalin-A (InIA) and internalin-B (InIB) that has 
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E-cadherin and Met as their respective major host-cell surface receptors (Mengaud et 
al., 1997; Shen et al., 2000). InIA interaction with E-cadherin activates β- and α-
catenin-mediated signaling pathways involved in the formation of adherens junctions. 
The initial signals triggered by the interaction of InIA with E-cadherin enhance the 
internalization of E-cadherin by Src-mediated tyrosine phosphorylation of E-cadherin 
followed by its ubiquitination by ubiquitin-ligase Hakai (Bonazzi et al., 2008).  
 
1.9.3 Other biological implications of Hakai 	  
Apart from the functional role of Hakai in cancer and infectious diseases, Hakai plays 
important role in other cellular processes and diseases. In a microarray profiling, 
Hakai was found differentially expressed during erythroid differentiation of murine 
erythroleukemia cells, suggesting the possibility of considering Hakai as a marker for 
erythropoiesis (Heo et al., 2005). Moreover, Hakai expression could be novel gene 
marker for immune-suppression in mouse lymph node assay (Oshida et al., 2011). 
 
1.10 Objectives 	  
Hakai is involved in the regulation of cell adhesion, cell migration and embryogenesis 
(Figueroa et al., 2009; Fujita et al., 2002; Gong et al., 2010; Kaido et al., 2009). 
Among the reported protein interactions of Hakai, its association and ubiquitination of 
the tyrosine phosphorylated E-cadherin upon Src activation is the best characterized 
(Fujita et al., 2002). The involvement of Hakai in modulating the E-cadherin mediated 
cell adhesion suggests that it participates in cancerous metastasis by disrupting the 
cell-cell contacts. Knowledge of the structure and function of Hakai, particularly the 
pTyr-binding domain of Hakai which binds the tyrosine phosphorylated E-cadherin 
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motif is crucial for understanding the whole process, as well as for identifying other 
potential targets of Hakai. 
 
Our earlier studies on the pTyr-binding domain of c-Cbl (Ng et al., 2008; Sun et al., 
2010; Sun et al., 2011) led us to examine the nature of the Hakai pTyr-binding 
domain to provide structural insights into its interaction with E-cadherin. Based on the 
sequence analysis, the Hakai pTyr-binding domain does not bear significant sequence 
homology with the known SH2 and PTB domains. Particularly, the putative pTyr-
binding domain of Hakai bears less than 8% sequence identity with the pTyr-binding 
domain of c-Cbl. Furthermore, based on sequence analysis, the Hakai pTyr-binding 
domain comprised of around 50 residues, which is significantly smaller than all the 
existing pTyr-binding domains including SH2 and PTB domains. In addition, the 
pTyr motif of E-cadherin that interacts with the pTyr-binding domain of Hakai 
appears to be very unique as it contains three consecutive Tyrosine residues (Figure 
1.26). Based on the uniqueness of the pTyr-binding domain of Hakai and the 
distinctive E-cadherin motif it recognizes, we hypothesize that a completely novel 










Figure 1.26 Unique features of Hakai pTyr-binding domain. Although Hakai share 
functional similarity with c-Cbl, its pTyr-binding domain appears to be completely 
different. Moreover, Hakai pTyr-binding domain bears no similarity with the existing 
SH2 and PTB domains.  
 
 
Thus, considering the unique features of Hakai pTyr-binding domain, the objectives 
of the present study are as follows: 
1. To identify and characterize the domain boundaries that defines the pTyr-
binding domain of Hakai 
2. To characterize and determine the structure of the Hakai pTyr-binding 
domain. This will delineate the exact nature of this unique domain, whether it 
is a minimal SH2 or PTB domain, or a novel pTyr-binding domain altogether 
3. To determine how Hakai pTyr-binding domain binds the pTyr motif of          
E-cadherin and validate the binding with point-mutational analyses using full-
length proteins 
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4. To experimentally determine the binding partners of Hakai pTyr-binding 
domain and characterize their interaction with Hakai pTyr-binding domain, 
and validate the findings using full length proteins 
5. To determine if Hakai like pTyr-binding exist in other human proteins by 
sequence based studies and experimental approaches 
6. To carry out NMR and other solution studies to gain better understanding 
about the additional attributes of the Hakai pTyr-binding domain  
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Structure and function of a novel phosphotyrosine-binding 
domain in Hakai- the HYB domain   
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2.1 Introduction 	  
In eukaryotic cells, phosphorylation events regulate cell signalling by providing 
docking sites for protein domains, such as the Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domains (Forman-Kay and Pawson, 1999; Pawson 
and Nash, 2003; Yaffe, 2002). The SH2 was the first signalling domain to be 
identified and has been extensively characterized (Filippakopoulos et al., 2009; 
Forman-Kay and Pawson, 1999; Liu et al., 2006; Pawson and Nash, 2003; Songyang 
et al., 1993; Yaffe, 2002). The SH2 is a dedicated phosphotyrosine-binding domain 
and plays a critical role in signal transduction, hence making it a target for drug 
development (Kasembeli et al., 2009; Machida and Mayer, 2005a; Pawson and Nash, 
2003; Taylor et al., 2008). Binding specificity of SH2 domains is generally conferred 
by the sequences flanking the C-terminus of the phosphotyrosine (pTyr), and motif 
recognition is usually relatively inflexible. The other major class of pTyr-binding 
domain is the PTB domain. The specificity of binding to the PTB domain is conferred 
typically by residues on the target that are N-terminal to the pTyr. However, the PTB 
domain also recognizes non-pTyr motifs (Farooq and Zhou, 2004; Forman-Kay and 
Pawson, 1999; Pawson and Nash, 2003; Smith et al., 2006; Yaffe, 2002). Atypical 
phosphotyrosine-binding domains have also been detected in PKCδ and the human 
M2 pyruvate kinase (PKM2) (Benes et al., 2005; Christofk et al., 2008). 
In 2002, Fujita et al (2002) discovered a novel ubiquitin E3 ligase protein that 
targeted pTyr sites on E-cadherin. The E3 ligase, Hakai, possesses three domains: a 
RING domain, a short pTyr recognition sequence and a proline-rich domain (Fujita et 
al., 2002). Hakai is involved in the regulation of cell adhesion, cell migration and 
embryogenesis (Figueroa et al., 2009; Gong et al., 2010; Kaido et al., 2009). Among 
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the reported protein interactions of Hakai, its association with and ubiquitination of E-
cadherin upon Src activation is the best characterized (Fujita et al., 2002). 
Based on molecular modeling, Fujita et al (2002) assumed the pTyr-binding domain 
of Hakai to be a derivative SH2 domain. Our previous experience analyzing the SH2 
domain of a similar E3 ubiquitin ligase, c-Cbl (Ng et al., 2008) led us to examine the 
nature of the Hakai pTyr-binding domain to provide structural insights into its 
interaction with E-cadherin. In this study, we report that the Hakai pTyr-binding 
domain consists of a homodimer formed at a structurally novel interface. Each 
monomer consists of two zinc-finger domains: a RING domain and a minimum pTyr-
binding domain that incorporates a novel, atypical zinc coordination motif. Both 
domains play key roles in dimerization. The Hakai pTyr-binding domain is therefore 
composed of four zinc-binding domains cooperating to bind pTyr residues surrounded 
by acidic amino acids. Whereas the RING domain appears in other proteins, the 
atypical zinc-binding domain component is a novel protein fold that incorporates an 
intertwined configuration. 
The work reported in this chapter was published in EMBO J (31:5:p 1055 – 1329). 
We have collaborated with Dr Guy Graeme, IMCB Singapore to conduct the  cell-
based experiments in his lab. Dr Chow Soah Yee and Dr Permeen Yusoff are mainly 
involved in these experiments from Dr Guy’s lab.   
2.2 Materials and Methods 	  
2.2.1 Plasmids 	  
For structural studies, Hakai constructs were cloned into a set of vectors for construct 
optimization. These include pGEX-6P-1 (GE Healthcare, UK), pGEX-4T-1 (GE 
Healthcare, UK), pET-32a (Novagen, USA), pET-M (modified pET-32a constructed 
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by removing the Trx tag and S tag), pET SUMO (Invitrogen, USA), pET-44a 
(Novagen, USA) and pET PPL His6 MBP LIC cloning vector (Addgene, Cambridge, 
MA, plasmid 37183, deposited by Scott Gradia). The final optimized constructs for 
structural studies were those in pGEX-6P-1 vector inserts corresponding to mouse 
Hakai (148aa-206aa) and Hakai (106aa-206aa), respectively. Point mutations for the 
constructs used in structural and biophysical studies were made using KAPA HiFi 
DNA Polymerase (Kapa Biosystems, USA).  
 
Mouse Hakai, human E-cadherin and avian v-Src were gifts from W. Birchmeier 
(Max- Delbrück-Center for Molecular Medicine, Germany), W. Hunziker (IMCB, 
Singapore) and X.M. Cao (IMCB, Singapore), respectively. Mouse cortactin was 
from Addgene (Cambridge, MA) (plasmid 26722, deposited by A. Weaver). Human 
ZNF645 and DOK1 were from Origene (Rockville, MD). Where necessary, the genes 
were cloned into pXJ40-HA or pXJ40-FLAG. Point mutants and truncates for 
mammalian cell based studies were generated using the proofreading Pfu DNA 
polymerase. 
 
2.2.2 Antibodies and reagents  	  
Mouse anti-FLAG M2, rabbit anti-FLAG and anti-HA, and agarose-conjugated anti- 
FLAG M2 beads were from Sigma-Aldrich (St. Louis, MO). Rabbit GST, cortactin, 
E-cadherin and DOK1 antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Protein A-conjugated agarose beads were from Roche Molecular 
Biochemicals (Germany). Mouse anti- E-cadherin and HRP-conjugated anti-phospho-
tyrosine PY20 were from BD Transduction Laboratories (Lexington, KY). Mouse 
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anti-β-actin was from Abcam (Cambridge, MA). 
2.2.3 Cell lines and transfection 	  
HEK293 cells were purchased from ATCC (Manassas, VA) and maintained as 
described (Yusoff et al., 2002). Transfections were performed using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 
 
2.2.4 Immunoprecipitation and immunoblotting 	  
Immunoprecipitation and immunoblotting were carried out as described (Yusoff et al., 
2002) with the following modifications. HEK293 cells were harvested 24 h post-
transfection with a lysis buffer containing protease inhibitors (Roche) and 1mM 
Na3VO4  (Na3VO4 is an inhibitor of protein tyrosine phosphatases, alkaline 
phosphatases and ATPases). Immunoprecipitations were performed using agarose-
conjugated anti-FLAG or protein-specific antibodies followed by incubation with 
protein-A-conjugated agarose beads at 4°C. 
 
2.2.5 Protein expression and purification 
  
Inserts corresponding to Hakai (aa 148-206) and Hakai (aa 106-206) were cloned into 
pGEX-6P-1 vector (GE Healthcare) using BamHI and SalI as the restriction sites and 
expressed as a GST-fusion protein in E. coli BL21 (DE3) cells. The cells were 
cultured in Luria Broth medium at 37°C until the A600 nm reached 0.6–0.7, IPTG and 
zinc sulphate were then added at concentrations of 0.15mM and 50µM, respectively, 
and growth continued for around 20 hours at 15°C. Cells were harvested by 
centrifugation (8000 × g, 10 min, 4°C), and the pellet was resuspended in lysis buffer 
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(50 mM Bis-Tris pH 6.5, 300mM NaCl, 10µM zinc chloride, 5% Glycerol, 0.5% 
Triton-X 100, 2mM DTT, 1mM phenylmethylsulfonylfluoride (PMSF) and 
homogenized using a French Press Cell Disrupter (Thermo Electron Corporation). 
Subsequently, the cell lysate was centrifuged at 18,000 rpm for 30 min at 4°C (JA-
25.50 fixed angle rotor, Beckman Coulter centrifuge) and the supernatant was allowed 
to bind to glutathione-sepharose resin (GE Healthcare) for 2-4 hours at 4°C and was 
subsequently washed with a buffer containing 50 mM Bis-Tris pH 6.5, 300mM NaCl, 
5% glycerol, 2mM DTT. After the washing step, an overnight on-column cleavage at 
4°C with GST-PreScission Protease (GE Healthcare) was performed to remove the 
GST tag. A major portion of GST and GST-PreScission Protease remained bound to 
the glutathione-sepharose resin and the flow-through containing the partially purified, 
untagged proteins were further purified using a Superdex 75 size exclusion column 
(GE Healthcare) equilibrated with a buffer containing 10 mM Bis-Tris pH 6.5, 
250mM NaCl and 5mM DTT. 
 
2.2.6 NMR spectroscopy and chemical shift perturbation analysis 	  
15N/13C-labelled Hakai (aa 106–206) was obtained from cultures grown in M9 media 
supplemented with 15N-labelled ammonium chloride and 13C-labelled glucose as the 
sole nitrogen and carbon sources, respectively. The labeled proteins were purified as 
described above. NMR spectra were acquired at 298 K in an 800-MHz NMR 
spectrometer (Bruker, Karlsruhe, DE). The backbone assignment was obtained using 
standard 15N-edited HSQC, HNCACB and CBCA (CO)NH experiments; side chains 
were assigned using standard 3D-TOCSY, 3D-NOESY and HCCH-TOCSY 
experiments. NMR data were processed using NMRPipe (Delaglio et al., 1995) and 
analysed by NMRView (Johnson and Blevins, 1994).  
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For the chemical shift perturbation analysis, the 2D 1H–15N-HSQC spectra for the 
15N-labelled Hakai (aa 106–206) were acquired in the absence or presence of the 
phosphorylated E-cadherin peptide. Perturbed residues on Hakai were assigned by 
superimposing the two HSQC spectra. 
 
2.2.7 Crystallization and structure determination 	  
SelMet-substituted Hakai (aa 106-206) was expressed in a methionine auxotroph 
(Doublie, 1997) and purified as described above. SelMet incorporation was verified 
by MALDI-TOF. 
 
SelMet Hakai (aa 106–206) crystals were grown at 289 K by the hanging drop vapour 
diffusion method. The protein (30 mg/ml) was mixed with an equal volume of 
reservoir solution (140mM Li2SO4; 100mM Tris, pH 7.8; 15mM Na2S2O3; 20–22% 
PEG 5000 MME; 1% isopropanol and 20–25% ethylene glycol). A complete SAD 
data set was collected to 1.9Å resolution at the synchrotron beamlines (NSLS, 
Brookhaven National Laboratory and the National Synchrotron Radiation Research 
Center [NSRRC], Taiwan) using a Quantum4-CCD detector (Area Detector Systems 
Corp., Poway, CA). The data sets were processed and scaled using HKL2000 
(Otwinowski and Minor, 1997). The crystals belonged to space group P6222 with 
a=64.66Å, b=64.66Å, c=121.04Å, and contained one molecule in the asymmetric 
unit. 
 
All four expected selenium sites in the asymmetric unit were located by SOLVE 
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(Terwilliger and Berendzen, 1999). Initial phases were developed by RESOLVE 
(Terwilliger, 2003); the overall figure of merit was improved to 0.83, and over 90% of 
the molecule was built automatically. The remaining parts of the model were built 
manually using COOT (Emsley and Cowtan, 2004) and alternatively refined by CNS 
(Brunger et al., 1998) and PHENIX (Adams et al., 2002). The final model was refined 
to a 1.9-A° resolution with an R-factor of 0.2175 (Rfree=0.2396) and analysed using 
PROCHECK (Laskowski et al., 1993). All structure-related figures were prepared 
using PyMOL (DeLano, 2002). 
 
2.2.8 Circular Dichroism spectrometry 	  
Far UV spectra (260–190 nm) of Hakai (aa 148–206) and Hakai (aa 106–206) and its 
mutants were measured using a Jasco J-810 spectropolarimeter in phosphate buffer 
(pH 7.5) at room temperature using a 0.1-cm path length and stoppered cuvettes. Six 
scans were recorded, averaged and the baseline subtracted. 
 
2.2.9 Isothermal Titration Calorimetry 	  
Phosphorylated and non-phosphorylated peptides of E-cadherin (residues 749–761); 
phosphorylated peptides of DOK1 (residues 356-366) and Cortactin (residues 477-
489) were titrated at a molar concentration of 800 µM against 100 µM of Hakai (aa 
106– 206) dimer in a VP-ITC microcalorimeter (Microcal, Northhampton, UK) at 293 
K. 30 titrations were carried out using 10-µl injections of the appropriate peptide into 
the sample cell containing Hakai (aa 106–206) and the data were analysed with a one-
site binding model using the Origin software package v7.0 supplied by Microcal. All 
measurements were repeated thrice. 
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2.2.10 Dynamic light scattering 	  
Dynamic light scattering studies were carried out on a DynaPro Light Scattering 
instrument (Protein Solutions, USA) at a protein concentration of 2 mg/ml, in a buffer 
containing 10mM Bis-Tris pH 6.5, 250mM NaCl and 5mM DTT. 
 
2.2.11 Liquid chromatography–mass spectrometry/mass spectrometry 	  
Immunoprecipitates were separated by SDS–PAGE, and stained with Coomassie Blue 
G250. Protein bands were excised and washed with 25mM ammonium bicarbonate 
(ABB) in 50% acetonitrile (ACN) buffer thrice. The proteins in the gel were reduced 
with 10mM DTT in 25mM ABB buffer, alkylated with 5mM iodoacetamide, 
dehydrated and digested with trypsin overnight. After in-gel digestion, the solution 
was transferred to a clean tube and sonicated for 30 min in the presence of 50 ml 50% 
ACN and 5% acetic acid for protein extraction. This extraction procedure was 
repeated three times; the pooled extracts were dried with a vacuum concentrator. The 
samples were processed and analysed as described (Zhang	  et	  al.,	  2010) using a LTQ-
FT ultra mass spectrometer (Thermo).  
 
For each experiment, MS/MS (dta) spectra were extracted from the raw data files 
using the extract_msn program in Biowork 3.3 (ThermoFinnigan). The extracted dta 
files were combined into a single file in the Mascot generic file (mgf) format. Except 
for the conversion of precursor mass from MHþ in dta to m/z in mgf, the fragment ion 
m/z and intensity values were used as determined. Proteins were identified by 
searching the combined data against the IPI human database (downloaded on 25 
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November 2009, including 86845 sequences and 35122 444 residues) via an in-house 
Mascot server (version 2.2.07). Two missing cleavages were allowed. Precursor ion 
and MS/MS fragment ion error tolerances were set to <10 ppm. and <20 ppm, 
respectively. A protein was accepted as a true positive if it had a significant score 
(P<0.05) and at least two unique peptides. 
 
2.2.12 PDB Accession Code 	  
The coordinates and structure factors have been deposited at the Protein Data Bank 
(PDB) with the accession code 3VK6. 
 
2.3 Results  	  
2.3.1 Determination of the minimum pTyr- binding domain in Hakai that 
interacts with tyrosine phosphorylated E-cadherin 
 
To establish the minimum region on Hakai necessary to bind to E-Cadherin we first 
reiterated the binding assay utilized by Fujita et al., 2002. From Figure 2.1A it can be 
seen that E-Cadherin binds to Hakai only when tyrosine phosphorylated by v-Src. In a 
number of later experiments we will only show the v-Src stimulated samples for 
clarity of presentation.  
 
To identify the region of interaction between E-cadherin and Hakai, we made a 
number of Hakai constructs (as indicated in Figure 2.1B and Figure 2.1D) and tested 
their ability to bind to overexpressed E-Cadherin after phosphorylation by v-Src. 
Experiments using these constructs are shown in Figure 2.1C and Figure 2.1E 
respectively, and the results indicated that the designated minimum pTyr-binding 
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domain consisted of amino acids 148-206, which is considerably smaller than the 
approximately 100 amino acid SH2 or PTB domain.  
 
In an additional experiment, we made a few more constructs of Hakai as indicated in 
Figure 2.1F to further confirm the minimum pTyr-binding requirement. Here we 
made an interesting observation and demonstrated that binding was stronger when the 
RING domain was also included in binding studies (Figure 2.1G right panel). It is 
notable that we had to attach GST to the 148-206 sequence of Hakai in order to stably 
express it. This indicates that Hakai (148-206) might require additional structural 
elements and stabilization factors to achieve a stable fold. 
 
Thus, the combined results demonstrates that Hakai (aa148-206) is the minimum 
pTyr-binding domain while Hakai (aa106-206) which includes the RING domain in 
addition to the minimum pTyr-binding domain binds stronger with tyrosine 





Figure 2.1 (A-C) Determining the minimum-binding region of Hakai. (A) Wild-type 
E-cadherin and Hakai were overexpressed in HEK293 cells in the presence or absence 
of v-Src. The arrow indicates a non-specific band. E-cadherin is separated into two 
bands by SDS-PAGE, and the lower band co-migrates with the non-specific band. (B) 
A schematic representation showing the domains and truncation constructs (H1–H6) 
of Hakai: RING (RING domain), pTyr-B (phosphotyrosine-binding domain), Pro-rich 
stretch (Proline-rich domain). (C) E-cadherin was co-transfected into HEK293 cells 
with the HA-tagged wild-type or truncation constructs of Hakai indicated in (B) to 




Figure 2.1 (D-G) Determining the minimum-binding region of Hakai (continued). 
(D) A schematic diagram showing the truncation constructs of Hakai (H7–H10). (E) 
HEK293 cells were co-transfected with E-cadherin plus HA-tagged wild-type Hakai 
or truncation constructs H7 to H10 to determine which section of the N-terminal 
region of Hakai is needed for interaction with E-cadherin. (F) A schematic 
representation of the Hakai constructs H11, H12, H7’ and H13. Construct H12 was 
cloned into the mammalian expression vector pXJ40GST. (G) Wild-type Hakai and 
the truncation constructs H11, H12, H7’ and H13 were co-transfected into HEK293 
cells with E-cadherin to determine the region of Hakai to which E-cadherin binds. 
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2.3.2 Construct optimization  	  
We experimentally identified that Hakai (aa 148-206) is the minimum pTyr-binding 
domain of Hakai. We also established that Hakai (aa 106-206), which contained both 
the RING domain as well as the minimum pTyr-binding sequence, binds stronger to 
tyrosine phosphorylated E-cadherin than the minimum pTyr-binding domain alone. 
Subsequently, we sought to gain structural and functional insights into the 
determinants of pTyr-binding present in Hakai. For this, we proceeded to express and 
purify both Hakai (aa148-206) as well as Hakai (aa106-206) in order to produce 
crystallization quality protein aimed for structure determination by employing X-ray 
crystallography.  
 
In order to purify multi-milligram quantities of protein of crystallization quality, we 
made around 50 different constructs of Hakai containing a range of domain 
boundaries including Hakai (aa148-206) and Hakai (aa106-206) in a number of 
expression vectors, as described in the Materials and Methods section. Some of the 
construct details are summarized in Table 2.1. Finally, the Hakai constructs in pGEX-
6P-1, that contains GST as solubility tag and a PreScission Protease cleavage site 
yielded stable protein, and the tag could be cleaved and separated by employing on-
column PreScission Protease cleavage (Figure 2.2 and Figure 2.3). The construct 
details and results are summarized in Table 2.1. The expression and purification of 
Hakai constructs (aa 148-206) and (aa 106-206) in pGEX-6P-1 is explained as 
Materials and Methods. The final gel filtration profiles of Hakai (aa 148-206) and 
Hakai (aa 106-206), and the protein purity as seen in SDS-PAGE are shown in Figure 
2.2 and Figure 2.3 respectively. The gel filtration profile of Hakai (aa 106-206) 
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indicated that it eluted as a dimer.  
 
 
Table 2.1 Construct optimization for structural studies. Construct optimization of 
Hakai (aa148-206) and Hakai (aa106-206) aimed to produce multi-milligram 




Figure 2.2 Purification of Hakai (aa 148-206). Gel filtration profile of Hakai (aa 148-
206) in Superdex-75 column. The protein was purified to homogeneity, as Hakai (aa 
148-206) eluted as a single peak in the gel filtration. Gel filtration fractions from the 
peak were analyzed through 15% SDS-PAGE analysis. The X-axis indicates the 





Figure 2.3 Purification of Hakai (aa 106-206). Gel filtration profile of Hakai (aa 106-
206) in Superdex-75 column. The protein was purified to homogeneity, as Hakai (aa 
106-206) eluted as a single peak and the fractions from the peak were analyzed 
through 15% SDS-PAGE analysis. The X-axis indicates the elution volume in mL; Y-
axis indicates the UV absorbance (at 280 nm) measured in mAU.   
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Upon obtaining the purified proteins for both Hakai constructs, viz. (aa 148-206) and 
Hakai (aa 106-206), we used Circular Dichroism (CD) experiment to analyze the 
folding and secondary structural elements of both the constructs. CD analysis 
however revealed that purified Hakai (aa 148–206) was unstructured (Figure 2.4), 
and, thus, was not suitable for crystallization. On the other hand, Hakai (aa 106-206), 
that contained both the RING domain and the minimum pTyr-binding domain was 
folded as revealed in the CD spectrum (Figure 2.4) and was well suited for the 
subsequent crystallization experiments. 
 
 
Figure 2.4 CD spectra of Hakai (aa 148-206) and Hakai (aa 106-206). Readout from 
Circular Dichroism (CD) analysis showing that Hakai (aa 148-206) has no well 
defined secondary structure when compared to Hakai (aa 106-206).  
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Dynamic Light Scattering (DLS) experiment was performed during sample 
concentration of Hakai (aa 106-206) and prior to crystallization screening, to analyze 
the homogeneity of the protein. DLS experiment indicated a dispersity index of 0.02 
at 30 mg/ml of protein, and this indicated that the Hakai (aa 106-206) was highly 
mono-dispersed and thus suitable for subsequent crystallization trials (Figure. 2.5). 
Also, the apparent molecular weight indicated by the DLS experiment suggested that 
Hakai (aa 106-206) existed as a dimer in solution. 
 
 
Figure 2.5 Dynamic Light Scattering (DLS) results for purified Hakai (aa 106-206). 
The apparent molecular weight of Hakai (aa 106-206) as indicated in the DLS results 
(~24 kDa) is twice compared the monomeric molecular weight (~ 12kDa), suggesting 
that Hakai (aa 106-206) exists as a dimer in solution 
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2.3.3 Crystallization and X-ray diffraction data of Hakai (aa 106-206) 
 
The Hakai sequence spanning amino-acid residues 106–206 (aa 106–206) that 
contained both the RING domain and the minimum pTyr-binding domain, as 
represented schematically in Figure 2.8A, was purified as described and used for 
crystallization screening. Initial crystallization conditions were identified from the 
Hampton Crystal Screen I (Hampton Research, CA) and Wizard III crystal screen 
(Emerald Biosciences) using hanging drop vapour diffusion method at 298K. The 
initial crystals were very tiny and did not diffract X-rays. 
 
A series of optimization steps were employed to improve the size and quality of the 
protein crystals. These included the variation of protein concentration, precipitant and 
salt concentration, use of additive screen, introduction of a paraffin oil barrier 
(Chayen, 1997) over the reservoir solution to slow down the equilibration rate to 
produce larger and better crystals, use of  sodium thiosulphate (Na2S2O3) to prevent 
intermolecular disulfide bridges (Bisacchi et al., 2006; Bordo' et al., 2001), 
modulation of temperature, and so on. Finally, after extensive optimization of the 
crystallization condition, diffracting diamond shaped crystals appeared after 10 days, 
and grew over a period of 20-25 days at 289K. The step-wise improvement in the 
crystal shape and quality through the optimization process is indicated in Figure 2.6. 
The final diffraction quality crystals were obtained by mixing 2 µl of protein (30 
mg/ml) with 2 µl of reservoir condition consisting of 140mM Li2SO4; 100mM Tris, 
pH 7.8; 15mM Na2S2O3; 20–22% PEG 5000 MME; 1% isopropanol and 20–25% 
ethylene glycol through hanging-drop vapour-diffusion method at 289K. The final 
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optimized conditions were used to grow the SeMet Hakai (aa 106-206) crystals as 
well.   
 
 
Figure 2.6 Crystallization of Hakai (aa 106-206). Systematic and step-wise 
improvement in the crystal shape and quality to obtain diffraction quality of Hakai (aa 
106-206) 
 	  
Since the SeMet crystals of Hakai (aa 106-206) were grown in the presence of 20-
25% ethylene glycol, they were directly picked from the crystallization drop and flash 
cooled in a N2 cold stream (100 K) with no additional cryo-protection step.	   A 
complete SAD data set was collected to 1.9Å resolution at the synchrotron beamlines 
(Figure 2.7). The crystal belonged to P6222 and the structure was solved using SAD 




Figure 2.7 Representative diffraction pattern of Hakai (aa 106-206) crystal. The data 









2.3.4 Crystal structure of Hakai (aa 106-206) 	  
2.3.4.1 Overall structure 	  
The crystal structure of Hakai (aa 106–206) was solved at 1.9Å resolution (Figure 
2.8). The striking feature of the crystal structure was the formation of a dimer from 
paired, anti-parallel Hakai (aa 106–206) monomers. Each monomer consisted of an 
N-terminal RING domain, followed by the C-terminal atypical zinc-binding domain 
that is contained within the experimentally derived minimum pTyr-binding domain. 
Furthermore, each monomer contained three zinc ions at three distinct sites. Two of 
the three-zinc coordinating sites lie in the RING domain, while the third zinc ion 




Figure 2.8 A novel protein fold in Hakai. (A) A schematic diagram of the Hakai 
protein. (B) The crystal structure of Hakai (aa 106–206) reveals a dimer in an anti-
parallel configuration. Each monomer contains three zinc coordination sites. Sites 1 
and 2 lie in the RING domain. Site 3 is shared between the two monomers. 
 
2.3.4.2 The RING domain of Hakai 	  
The Hakai RING domain (residues 106–148) adopted a typical RING domain fold 
stabilized by coordinating with two zinc ions, forming a cross-brace arrangement 
(Figure 2.9) (Borden, 2000). The zinc- coordinating residues in the RING domain are 




Figure 2.9 RING domain of Hakai highlighted under the box. The coordination of 





Figure 2.10 A schematic diagram of the cross-brace arrangement of the Hakai RING 
domain. The Zinc ions are shown in the purple and the zinc coordinating Cysteine and 
Histidine residues within the RING domain are indicated. 
 
The Hakai RING domain (aa 106-148) was compared with the existing structures in 
the Protein Data Bank (PDB) using the DALI server 
[http://ekhidna.biocenter.helsinki.fi/dali_server/] (Holm et al., 2008). The RING 
domain of Hakai shows the highest structural similarity to Polycomb complex protein 
BMI-1, PDB code 2CKL (Buchwald et al., 2006), with rmsd of 1.9Å for 42 Cα atoms 
(Z-score= 4.3 ; 36% sequence identity. The next significant structural similarity of the 
Hakai RING domain was that with the RING domain of c-Cbl, PDB code 2Y1N (Dou 
et al., 2012a), with rmsd of 1.8Å for 40 Cα atoms (Z-score= 4.3 ; 25% sequence 
identity. Interestingly, the Hakai ring domain also bears significant structural 
similarity with CHIP U-box domain, PDB code 2OXQ (Xu et al., 2008), with rmsd of 
2.0 Å for 41 Cα atoms (Z-score= 4.3 ), although the sequence similarity is just 5%. 
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Thus, the analysis suggested that although the RING domain of Hakai is structurally 
similar to a number of the RING domains as well as U-box domain, but bears very 
low sequence similarity with other RING domains. Table 2.3 summarizes the DALI 
results indicating the representative structures of the RING and U-box domains that 
bear structural similarity with the Hakai RING (aa 106-148).  
 
 
Table 2.3 Structural comparison of Hakai RING domain with structural homologs. 
Representative structural matches of the Hakai RING domain (aa 106-148) searched 
in the PDB using DALI server 
  
2.3.4.3 A novel protein fold in Hakai: The minimum pTyr-binding region 	  
The uniqueness of the Hakai (aa 106–206) region was revealed when the structure 
was compared with other proteins in the PDB (Protein Data Bank) using the DALI 
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server [http://ekhidna.biocenter.helsinki.fi/dali_server/] (Holm et al., 2008). The 
results show that only the RING domain of Hakai is structurally similar to RING 
domains of other proteins. There is, however, no similarity beyond amino-acid 
residue 159 of the Hakai minimum pTyr-binding domain, which is located on the 
dimerization interface (Figure 2.11). The minimal pTyr-binding domain of Hakai 
adopts a novel, three-dimensional fold and contains three β-strands (β4, β5 and β6) 
and a C-terminal α-helix. The β-strands β4, β5 and β6 were in an extended 
configuration and formed anti-parallel β-sheets with the corresponding β-strands of 
the monomeric partner during homodimerization (Figure 2.12).  
 
 
Figure 2.11 Results of DALI search for Hakai (aa 106-206). Multiple structural 
alignment of Hakai (aa 106-206) with the structural matches from Protein Data Bank 
(PDB) using DALI server showing secondary structure assignments by DSSP 




Figure 2.12 A novel fold in the Hakai minimum pTyr-binding region. The minimum 
pTyr-binding domain of Hakai involves in dimerization in an intertwined 
configuration spanning the points indicated in circles, with the entry and exit paths 
shown in green and brown arrows. The zinc-interacting side chains are shown as 
green and brown sticks. 
 
2.3.4.4 Atypical zinc-finger motif in the minimum pTyr-binding region mediates 
dimerization  	  
The primary sequence of Hakai (aa106–206) suggests that each monomeric unit 
fulfills the required criteria of the zinc coordination consensus pattern of cysteine and 
histidine residues [C-x(5)-C-x(12)-H-x(4)-H] (Figure 2.13A). However, the crystal 
structure reveals that the single monomer unit is not capable of forming the zinc 
coordination sphere by itself, since a second cysteine residue is required of its anti-
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parallel monomeric partner (Figure 2.13B). Thus, the structure confirms the formation 
of two atypical zinc-finger motifs within this region formed by two histidine residues 
(H185 and H190) and one cysteine residue (C172) from one monomer and a second 
cysteine residue (C166) from the adjacent monomer (Figure 2.13B and Figure 2.14). 
Therefore, each dimer contains two atypical zinc-finger motifs.  
 
 
Figure 2.13 Atypical Zinc finger motif (ZnF) in dimer interface. (A) Primary 
sequence of Hakai (aa 106-206) suggests the presence of the consensus sequence of a 
typical zinc finger. (B) Crystal structure reveals the presence of an atypical ZnF, in 
which two histidines and one cysteine is contributed from one monomer, while the 
second cysteine comes from the adjacent monomeric partner, resulting the formation 




Figure 2.14 Stereo view of the atypical zinc finger motif. The final 2Fo-Fc electron 
density map contoured at 1.5σ is shown in stereo view. The zinc-coordinating 
residues and the zinc ion at the dimer interface are shown. 
 
 
2.3.4.5 Extensive H-bonding interactions and metal coordination defines a novel 
dimer interface 	  
The crystal structure of Hakai also shows that the two Hakai monomers configure 
themselves to form a wide range of favorable intermolecular interactions, resulting in 
the formation of three β-sheets based on 12 main-chain hydrogen bonds (Figure 2.15 
and Figure 2.16). This novel interlinked configuration, extensive H-bonding networks 
and the two atypical zinc ion interactions at the dimer interface are unique features of 
this distinctive homodimeric assembly. 
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Figure 2.15 Interactions at the dimer interface. The backbone of the Hakai (aa 106–
206) residues involved in intermolecular main-chain H-bonding and the zinc-
coordinating side chains of adjacent monomers at the dimer interface are shown in 
cyan and yellow. The pink dots indicate the main-chain H-bonds; the red dots indicate 
the zinc coordination bonds 
 
 
Figure 2.16 The 2F0-Fc map contoured at 1.5σ showing electron density of zinc 
coordination residues at the dimer interface of Hakai (aa 106-206). 
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2.3.4.6 Hakai dimerization involves novel intertwining of the two monomeric 
units 	  
The crystal structure of Hakai also shows that the two Hakai monomers intertwine 
through a stretch of residues ranging from F164 to Y176 during dimerization (Figure 
2.17 and Figure 2.18). A surface area of ~1650Å2 of each monomer (or ~21% of each 
monomer surface) was formed at the dimer interface of Hakai (aa 106–206), with 34 
hydrogen bond contacts between the monomers, as analyzed by the PISA server 
(Krissinel and Henrick, 2007). 
 
 
Figure 2.17 The monomers of the interlinked Hakaidimer are shown in surface 
representation and Cα trace, respectively. The Cα trace monomer enters and exits the 
other monomer at the red and black circles, respectively. Brown arrows show its entry 




Figure 2.18 A schematic diagram of the novel Hakai intertwined dimeric 
arrangement 
 
2.3.4.7 Comparison with dimeric RING E3 ligases: Hakai dimer reveals a unique 
‘trans’ RING-RING configuration 	  
Many members of the RING finger ubiquitin ligase family function as dimers. 
Dimerization generally occurs through the RING finger domain or surrounding 
regions and can result in homodimers or heterodimers. For heterodimers, one RING 
domain often lacks ligase activity and might conform and/or stabilize the active E2-
binding RING domain. A list of the dimeric RING ligases whose structure has been 
solved is tabulated in Tables 2.4 and 2.5. A notable feature of all the known dimeric 
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RING ligases is the RING-RING configuration of the dimeric assembly. So far, in all 
the dimeric RING ligases, be it homodimer or heterodimer, the RING domains of the 
respective monomers face in the same side to form a ‘cis’ RING-RING configuration. 
However, the dimeric Hakai structure revealed that the RING domains of the two 
monomer lie across each other in the so-called ‘trans’ configuration. This type of 
RING configuration is likely to demonstrate novel ubiquitin conjugation and transfer 
mechanism from the E2 enzyme to the substrates, in comparison to other dimeric 
RING ligases where the RING domains lie in cis- configuration. A comparison of the 
RING-RING arrangement of Hakai with the known dimeric RING E3 ligases is 
shown in Figure 2.19.  
 
S.N. PDB code Description Reference 
1 4AUQ BIRC7 (Dou et al., 2012b) 
2 2Y43 RAD18 (Huang et al., 2011) 
3 3EB5 cIAP2 (Mace et al., 2008) 
4 2YHN IDOL (Zhang et al., 2011) 
5 3NG2 RNF4 (Liew et al., 2010) 
6 1RMD RAG1 dimerization domain (Bellon et al., 1997) 
7 3HCS TRAF6 (Yin et al., 2009) 
 
Table 2.4 List of homodimeric RING ligases whose structures have been solved 
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S.N PDB code Description  Reference 
1 2CKL RING1B-BMI1 
heterodimer 
(Buchwald et al., 2006) 
2 1JM7 BRCA1/BARD1 
heterodimer 
(Brzovic et al., 2001) 
3 2VJF Mdm2-Mdmx 
heterodimer 
(Linke et al., 2008) 
Table 2.5 List of heterodimeric RING ligases whose structures have been solved. 
These include [(MDM2 and MDMX), (BRCA1 and BARD1), (RING1b and BMI1)] 
For heterodimers, one RING domain (MDMX, BARD1, BMI1) often lacks ligase 




Figure 2.19 Comparison of the RING-RING arrangement of Hakai dimer with the known dimeric RING E3 ligases. The RING domains 
of the respective Hakai monomers lie across each-other to form a trans RING-RING arrangement, whereas in all the know dimeric E3 
RING ligases, the RING domains of the monomeric units face the same side to form a cis RING-RING configuration. 
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2.3.5 Hakai forms a dimer in solution 	  
In addition to the crystal structure, the intermolecular NOE cross-peaks corresponding 
to the amides of residues at the dimer interface also indicates that Hakai (aa 106–206) 
forms a dimer in solution (Figure 2.20). Significantly, the structures of the 
dimerization interface of the RAG1 domain (Bellon et al., 1997) and Hakai (aa 106–
206), as described in this study, are completely dissimilar. The formation of Hakai (aa 
106–206) dimers in solution is also supported by the results obtained through 
dynamic light scattering, which show an apparent molecular weight of 24.1 kDa, 
twice than that of the monomer (Figure 2.5). 
 
We next examined whether zinc coordination is necessary for the dimerization of 
Hakai and its ability to interact with its target. We first investigated whether 
mutations of the zinc coordinating-residues within the minimum pTyr-binding domain 
(C166, C172, H185 and H190) would affect the proposed Hakai dimerization. The 
Hakai (aa 106–206) polypeptides containing point mutations at these residues were 
separated on a calibrated gel-filtration column. Their gel-filtration elution profiles 
show that each point mutant had an apparent molecular weight equivalent to a 
monomeric unit of wild-type (WT) Hakai (aa 106–206) protein (~12kDa), whereas 
WT Hakai eluted as a dimer (Figure 2.21). Furthermore, circular dichroism performed 
using all the Hakai (aa 106–206) mutants ascertained that each one has maintained a 
well-defined secondary structure (Figure 2.22). These findings suggest that each zinc-




Figure 2.20 Hakai forms a dimer in solution. A 3D 15N-NOESY spectrum showing 





Figure 2.21 Importance of the zinc-coordination on Hakai dimerization. WT Hakai 
(aa 106–206) and four Hakai (aa 106–206) point mutants were each separately used 





Figure 2.22 Secondary structure of Hakai (aa 106 – 206) zinc-coordinating mutants. 
Circular dichroism analysis shows that each of the zinc-coordinating mutants of Hakai 
(aa 106 – 206) maintained a well-defined secondary structure, comparable to that of 
the wild type 
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Having determined that Hakai (aa 106–206) dimerizes in solution, we next examined 
if this occurs with full-length proteins. Full-length FLAG-tagged Hakai was observed 
to bind to its HA-tagged counterpart (Figure 2.23), indicating that dimerization also 
occurs between the full-length proteins. 
 
Figure 2.23 Full-length Hakai exists as dimer inside cells. HA- and FLAG-tagged 
Hakai were overexpressed in the presence of Src in HEK293 cells. FLAG 
immunoprecipitates were analyzed for HA-tagged Hakai  
 
To further determine whether Hakai dimerization is required for its function in 
binding its targets, the full-length proteins containing alanine point mutations of the 
zinc-coordinating residues (Figure 2.24A) were tested for their ability to bind to 
tyrosine-phosphorylated E-cadherin. HEK293 cells were used for such studies, as 
they did not express detectable levels of endogenous E-cadherin, which could have 
interfered with the mammalian cellular assays used. The evidence presented in Figure 
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2.24B indicates that none of the four Hakai point mutants interacted with tyrosine-
phosphorylated E-cadherin. The collective results therefore show that zinc 
coordination is necessary for both dimerization of Hakai and its subsequent function 
in interacting with its target. 
 
 
Figure 2.24 Hakai dimerization is necessary for binding tyrosine phosphorylated E-
cadherin. (A) A schematic representation of the point mutations made to C166, C172, 
H185 and H190 in Hakai. (B) Cell lysates containing WT Hakai or Hakai mutants 
were used to analyze the effects of Hakai dimerization on E-cadherin recognition. 
 
 
2.3.6 Phosphorylation of a single tyrosine residue of the triple tyrosine-
containing E-cadherin motif  (YYY motif) is sufficient for binding with Hakai 	  
Having established the novel characteristics of the Hakai zinc-coordinated 
homodimer, we sought to identify the target motif of this new domain. At this point, 
the only described target motif was in Src-phosphorylated E-cadherin. Within this 
motif, two (Y755 and Y756 in mouse; Y753 and Y754 in humans) of three 
consecutive tyrosine residues were reported to be involved in the interaction with 
Hakai (Fujita et al., 2002). To analyze the relative contributions of the three-tyrosine 
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residues in binding to Hakai, mutations were made to the tyrosine residues (Figure 
2.25A). To determine which of the tyrosines were phosphorylated, we analyzed the 
patterns of the tyrosine phosphorylation of the point mutants after v-Src activation. 




Figure 2.25 Analysis of the pTyr signals of Src phosphorylated E-cadherin. (A) 
Y753, Y754 and Y755 (red) of E-cadherin were mutated to phenylalanine (blue) in 
different combinations. (B) The WT E-cadherin and the mutants shown in (A) were 
overexpressed in HEK293 cells with v-Src to analyze their pTyr signals. 
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We next examined the importance of the three-tyrosine residues in E-cadherin for its 
interaction with Hakai. The E-cadherin mutants used in the earlier experiment were 
analyzed for their potential to bind to WT Hakai. The results shown in Figure 2.26A 
indicate that Y754 is the only tyrosine significantly involved in binding; each mutant 
containing a substitution in this position did not bind Hakai, whereas all other mutants 
showed significant binding. These combined results also show that while Src binds to 
and phosphorylates most of the E-cadherin mutants, all the mutants with a Y754F 
substitution do not bind to Hakai, even when phosphorylated. This implies that the 
interaction between Hakai and E-cadherin depends on the direct recognition of 
specific pTyr residues on E-cadherin by Hakai. To verify the necessity of Y754 
phosphorylation for the interaction between E-cadherin and Hakai, isothermal 
titration calorimetry (ITC) was performed using phosphorylated and non-
phosphorylated E-cadherin peptides corresponding to aa 749–761 with Hakai (aa 
106–206). The results in Figure 2.26B show that binding occurred only with the 
phosphorylated peptide. Furthermore, the results (2.26B) also indicate that only one 
E-cadherin peptide binds to the Hakai (aa 106–206) dimer at any one time. 
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Figure 2.26 Phosphorylation of a single Tyrosine of E-cadherin (Y754) is critical for 
binding. (A) HEK293 cells were co-transfected with WT E-cadherin or its mutants 
together with Hakai to identify the tyrosine residues recognized by Hakai. (B) The 
Y754-phosphorylated and non-phosphorylated E-cadherin peptides were titrated 
against Hakai (aa 106–206) using ITC. The top panels show the heat release profiles 
after baseline correction and the lower panels indicate the binding isotherms for the 
interactions. The dissociation constant (Kd) and binding stoichiometry (N) are shown 
in the table. 
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2.3.7 Hakai domain recognizes acidic residues 	  
In a similar manner, we analyzed the importance of the amino-acid residues flanking 
the tyrosines for the interaction between the two proteins via an alanine scan (Figure 
2.27A). The immunoprecipitation results in Figure 2.27B show that there were 
profound contributions from aspartic acid D756 and glutamic acid E757, and 
significant contributions from valine V752 and aspartic acid D750. Consequently, a 
cluster of negative charges from the acidic amino acids is formed around the centrally 




Figure 2.27 Hakai pTyr-binding domain binds acidic residues. (A) The E-cadherin aa 
747–758 were each substituted with alanine. (B) The E-cadherin mutants from (A) 
and Hakai were co-transfected into HEK293 cells to identify the target motif on E-
cadherin. The results suggest that the central phosphotyrosine residue is most 
important for binding with Hakai. 
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2.3.8 Identification of novel substrates of Hakai pTyr-binding domain 	  
To verify the motif recognized by Hakai, additional target proteins were identified. 
This identification was accomplished by analyzing Hakai-binding proteins 
phosphorylated by Src using mass spectrometry. A list of the proteins obtained from a 
typical experiment is appended below and Figure 2.28 provides details about the 
identification of cortactin as a potential target. The list  
 
1. Protein phosphatase 1B isoform 1 
2. Protein phosphatase 1A 
3. Protein phosphatase 1 regulatory subunit 12A 
4. casein kinase I delta 
5. Casein kinase I isoform epsilon 
6. CTTN Src substrate cortactin 
7. DOK1 
8. cAMP-dependent protein kinase type I-alpha regulatory subunit 
9. ILF2 Interleukin enhancer-binding factor 2 
10. IRS4 Insulin receptor substrate 4 
11. IRAK1 interleukin-1 receptor-associated kinase 1 isoform 3 
12. JAK1 Tyrosine-protein kinase JAK1 
13. Protein kinase C iota 
14. Protein kinase C delta 
15. Isoform 1 of Nck-associated protein 1 mammary tumor-associated protein 
INT6 
16. ARHGAP21 Rho GTPase activating protein 21 
17. Human rab GDI 
18. LIM domains containing 1 
19. phosphoinositide-3-kinase, regulatory subunit 4 
20. Phosphatidylinositol 4-kinase alpha 
21. E3 ubiquitin-protein ligase BRE1B RNF40 
22. E3 ubiquitin-protein ligase BRE1A RNF20 
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 Figure 2.28. Hakai interacts with Cortactin. Mascot spectra read-out.     
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Mouse cortactin is phosphorylated by Src primarily on Y482 and Y485 (Ren et al., 
2009). Interestingly, these two tyrosines are also surrounded by several acidic 
residues. Initially, Isothermal titration calorimetry (ITC) was used to verify the 
binding of this Cortactin motif that contains the two phosphorylated tyrosines 
surrounded by acidic residues binds with Hakai pTyr-bind domain. The result shown 
in Figure 2.29 clearly reveals that the Hakai pTyr-binding domain binds with 
Cortactin with significant affinity. 
Figure 2.29 Binding studies of Hakai (aa 106-206) with Cortactin using ITC. The 
tyrosine phosphorylated Cortactin was titrated against Hakai (aa 106–206) using ITC. 
The top panels show the heat release profiles after baseline correction and the lower 
panels indicate the binding isotherms for the interactions. The dissociation constant 
(Kd) and binding stoichiometry (N) are shown in the table. 
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As the ITC experiment confirmed the binding of the tyrosine phosphorylated 
Cortactin with Hakai (aa 106-206), we subsequently validated the idea that whether 
full length Hakai binds Src-phosphorylated cortactin, as well as the importance of 
Y482, Y485 and their flanking residues in this interaction. In addition to the WT 
proteins, phenylalanine substitution and alanine scan experiments were also 
performed on cortactin as described for E-cadherin. The results for cortactin mirror 
those obtained for E-cadherin. Like E-cadherin, cortactin interacts with Hakai only 
when phosphorylated by Src (Figure 2.30). Phenylalanine substitutions of the Src-
phosphorylated tyrosine residues revealed that Y482 is the main tyrosine residue 
involved in Hakai binding (Figure 2.31). Furthermore, the acidic residues (E478, 
D480 and E486) surrounding Y482 contributed profoundly to the interaction between 
Hakai and E-cadherin, and significant contribution was also observed from S487 
(Figure 2.32).  
 
 
Figure 2.30 In the similar manner as E-cadherin, Cortactin interacts with Hakai only 
when phosphorylated by Src. (A) E-cadherin and Hakai were co-transfected into 
HEK293 cells. Their interaction was analyzed through immunoprecipitation of 
FLAG-tagged Hakai. (B) Cortactin was co-transfected into HEK293 cells with Hakai. 
The interaction between cortactin and Hakai was compared with that in (A). The data 
clearly shows that cortactin binds Hakai in a pTyr-dependent manner in a way similar 





Figure 2.31 Y482 is the main tyrosine residue of Cortactin that is involved in Hakai 
binding. (A) Y482 and Y485 (red) were separately substituted with phenylalanine 
(blue). (B) WT and mutated cortactin were co-transfected into HEK293 cells with 
Hakai, in the absence or presence of v-Src. The pTyr signal of Cortactin and its 
interaction with Hakai were analyzed.  
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Figure 2.32 Hakai recognizes acidic residues of Cortactin. (A) An alanine scan of 
cortactin aa 478–489. Each residue was substituted with alanine (blue). G484 was not 
mutated as glycine mutations affect the protein structure. (B) The cortactin mutants 
described in (A) were co-transfected into HEK293 cells with Hakai. The interaction 
between the cortactin mutants and Hakai was determined using immunoprecipitation. 
  
The binding patterns of Hakai with E-cadherin and Cortactin suggested that Hakai 
recognizes Src phosphorylated tyrosine residue flanked by acidic amino acids. Thus, 
in order to further verify that Hakai targets pTyrs of Src substrates with surrounding 
acidic residues, another Src substrate was selected: DOK1, which also contains pTyrs 
with adjacent acidic groups (Luo et al., 2008). One such particular tyrosine residue 
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was found to be a primary phosphorylation site of Src (Luo et al., 2008) (Figure 
2.33A). The results show that DOK1 interacts with Hakai (Figure 2.33B). 
Furthermore, DOK1 competed with endogenous Cortactin for Hakai, implying that 
DOK1 and Cortactin bind Hakai on the same site (Figure 2.33C). We also measured 
the binding affinity of the DOK1 pTyr motif with Hakai (aa 106-206) using ITC, 




Figure 2.33 DOK1 interacts with Hakai. (A) The sequence alignment of the different 
Src phosphorylation target sites in E-cadherin, cortactin and DOK1. The acidic 
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amino-acid residues flanking the phosphorylated tyrosine are shown in blue. (B) 
Hakai and DOK1 were overexpressed in HEK293 cells in the absence or presence of 
Src. FLAG immunoprecipitates were analysed for DOK1 interaction. (C) DOK1 was 
co-transfected into HEK293 cells with Hakai to study its competition with 
endogenous cortactin for binding to Hakai. FLAG immunoprecipitates were 













DOK1356-366 KEDPIpYDEPEG 1.156+0.006 0.1923+0.008 5.2 -7.445+0.048 -0.237 -7.208 
 
Figure 2.34 Binding studies of DOK1 with Hakai using ITC. The tyrosine 
phosphorylated DOK1 was titrated against Hakai (aa 106–206) using ITC. The top 
panels show the heat release profiles after baseline correction and the lower panels 
indicate the binding isotherms for the interactions. The dissociation constant (Kd) and 
binding stoichiometry (N) are shown in the table. 
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2.3.9 Determination of target-binding amino acids of Hakai 	  
To identify the residues in Hakai within aa 106–206 necessary for its interaction with 
E-cadherin, 2D 1H–15N-HSQC spectra of 15N-labelled Hakai (aa 106–206) were 
acquired in the absence and presence of a pTyr peptide derived from amino-acid 
residues 749–761 of E-cadherin. Based on the changes in the NMR spectrum of Hakai 
(aa 106–206), several residues underwent perturbations in chemical shift (Figure 2.35 
and 2.36). A minimum criterion of a chemical shift difference Δδp.p.m. > 0.15 p.p.m. 
was applied. Five residues were identified (Y176, H185, N187, H188 and R189), 
which resided in the Hakai minimum pTyr-binding domain, whereas a sixth residue 
(H127) was from the RING domain (Figure 2.37). However, the crystal structure 
shows that only four of these six residues reside in a close three-dimensional spatial 
proximity. While H127, Y176, H185 and R189 face the interior of the E-cadherin-
binding site (Figure 2.37) and form a positively charged pocket, N187 and H188 face 
outward and are not part of the pocket (Figure 2.38).  
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Figure 2.35 NMR chemical shift perturbation experiment. An overlay of the 1H–15N-
HSQC spectra of Hakai (aa 106–206) in the absence (green) or the presence (red) of a 




Figure 2.36 Graphical representation of chemical shift perturbation. A graphical representation of the combined chemical shift 





Figure 2.37 Mapping of E-cadherin interacting residues on Hakai. The six potential 
E-cadherin-interacting residues in Hakai (aa 106–206) are highlighted as sticks in the 
ribbon representation of the crystal structure. The crystal structure shows that only 
four of these six residues reside in a close three-dimensional spatial proximity and 
face the interior of the E-cadherin-binding site, whereas, N187 and H188 face 





Figure 2.38 A positively charged pTyr-binding pocket in Hakai. An electrostatic 
surface potential representation of Hakai (aa 106–206) shows that H127, Y176, H185 
and R189 form part of the positively charged pocket. 
 
 
These residues identified through in vitro peptide-domain binding assays were then 
further tested by expressing full-length point mutants in HEK293 cells. The 
immunoprecipitation results shown in Figure 2.39 indicate that the residues identified 
in the NMR analysis also abrogated binding when mutated, with the exception of 
residues N187 and H188. As expected, the required residues were situated on the 
interior of the target-binding domain, whereas the non-binding residues, N187 and 
H188, were on the exterior. Similar results were obtained with experiments using 
Cortactin (Figure 2.40A), demonstrating the importance of these Hakai residues. 
Furthermore, dimerization of Hakai is also required, as with E-cadherin, as cortactin 
was unable to bind to Hakai containing mutations to its zinc-coordinating residues 




Figure 2.39 Cell based validation using full length Hakai/E-cadherin binding. The 
interaction between E-cadherin and the Hakai mutants of the residues identified by 
NMR and shown in (Figure 2.38) was analyzed by immunoprecipitating FLAG-





Figure 2.40 Cell based interaction studies for validation of Cortactin binding residues 
of Hakai. As was the case with E-cadherin, the Hakai residues identified by NMR 
together with Hakai dimerization are important for binding with Cortactin. (A) 
HEK293 cells were transfected with the identified Hakai mutants, and their 
interaction with endogenous cortactin was studied. (B) Immunoprecipitates of either 





Based on NMR data and mutational studies, a computational model was generated 
using Haddock  (http://haddock.science.uu.nl/services/HADDOCK/haddock.php), 
which further confirms that the recognition sequence on E-cadherin would fit into the 




Figure 2.41 A computational model based on the NMR data and mutational analyses 
shows that E-cadherin fits into the binding pocket of Hakai. (A) Ribbon 
representation showing the binding mechanism of Hakai (aa 106-206) with  the E-
Cadherin747-760  peptide (B) Electrostatic surface potential representation of Hakai (aa 
106-206) in the same orientation as shown in (A) indicating that the E-cadherin motif 
fits into the positively charged pocket of Hakai.   
 
 
Based on the evidence obtained, it can be concluded that two Hakai monomers 
interact in an anti-parallel manner to form a dimer via the interlinked zinc-
coordinating domain. This domain binds pTyrs flanked by acidic amino acids in Src 
substrates. The target-binding domain resulting from this dimerization process 
represents the functional Hakai phosphotyrosine-binding domain, henceforth referred 
to as the HYB (Hakai pY-binding) domain (Figure 2.42). 
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Figure 2.42 A schematic representation of the Hakai dimer and the HYB domain. 
 
2.3.10 The HYB domain in other proteins 
 
We next investigated whether the HYB domain is found in other proteins. Literature 
and database searches revealed that the testis-specific ubiquitin E3 ligase ZNF645 
exhibited high sequence homology with Hakai (Liu et al., 2010), as shown in Figure 
2.43A. We therefore questioned whether ZNF645 could also interact with E-cadherin 
and cortactin. The results in Figure 2.43B show that ZNF645 bound to v-Src-
phosphorylated E-cadherin but not to cortactin (Figure 2.43C). This result implies that 
although there is significant homology between Hakai and ZNF645, they are likely to 
have their own sets of targets due to the differences in their sequences between the 
key zinc-coordinating residues. 
 
 
Figure 2.43 The HYB domain in other proteins. (A) A comparison of the Hakai 
protein from amino-acid residues 127–191 and the equivalent sequence in ZNF645. 
(B) E-cadherin and ZNF645 were analysed for their interaction using 
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immunoprecipitation. Hakai was used as a positive control. The dotted arrow 
indicates a non-specific band; the solid arrow indicates the ZNF645 band. (C) 
ZNF645 was overexpressed in HEK293 cells and its interaction with endogenous 
cortactin was analyzed using immunoprecipitation. 
 
Based on the key amino-acid residues involved in zinc coordination and binding in 
HYB, we searched the NCBI database to analyze gene origins and protein homologies 
(Table 2.6). Two interesting results emerged. First, a comparison of the species 
distribution of the Hakai and ZNF645 gene products indicated that the latter, found 
only in primates, is most likely a recent copy of the former. Second, ZNF645 is an 
intronless gene, implying that it is a retrotransposed copy of Hakai. 
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Table 2.6 List of proteins with sequences that potentially match the region of Hakai 
from amino acid residues 127 to 189. 
 
Further database searches based on the conserved zinc-coordinating cysteine and 
histidine residues within the HYB domain showed that a similar series of residues is 
present in LNX1 and LNX2 (Figure 2.44). This implies that the HYB domain may be 
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Figure 2.44 Sequence alignment of LNX1 and LNX2 with Hakai and ZNF645 based 
on the conserved zinc-coordinating residues from Hakai aa 106–206. 
 
 
2.3.11 Novel structure of the HYB domain 
 
The structures of all the five pTyr-binding domains that have been discovered to date, 
which also includes the two idiosyncratic pTyr-binding domains (C2 domain of PKCδ 
and PKM2), are illustrated in Figure 2.45A and B. All of the domains, except for the 
HYB domain, are contained within one monomer. The HYB domain consists of a pair 
of monomers arranged in an anti-parallel configuration and is composed of two RING 
and two atypical zinc-coordinating domains. From this comparison, it is apparent that 
all five of these pTyr domains have completely different structures, with different 
strategies to recognize tyrosine phosphorylation. 
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Figure 2.45 Novel structure of the HYB domain. (A) Representative structures of 
SH2 (PDB code 1SHB), PTB (PDB code 1SHC), PKCd C2 (PDB code 1YRK) and 
PKM2 (PDB code 3BJF) in ligand-free forms are compared with the HYB domain. 
(B) The corresponding topologies of the domains in (A). 
 109 
2.4 Discussion 	  
Zinc fingers (ZnFs) consist of a diverse group of protein domains that are able to bind 
to zinc ions. Initially thought to bind only nucleic acids, ZnFs were later shown to 
mediate protein– protein interactions (Gamsjaeger et al., 2007; Klug, 2010). The 
common structural feature in the different ZnF classes, where determined, is that the 
zinc-coordinating cysteine and histidine residues are all situated on the same 
monomer. The evidence in this study has shown that Hakai, in addition to having a 
typical RING domain, possesses an atypical ZnF with a novel structural fold. In 
contrast to previously reported structures, the formation of this atypical ZnF requires 
amino acid residues from two intertwining Hakai monomers. Three of the four 
residues are contributed by one monomer, whereas one cysteine residue comes from 
another monomer, implying that the formation of this ZnF is accompanied by 
dimerization. Although this particular ZnF is novel by itself, it is made more 
intriguing by the fact that this domain lies within a pTyr-binding region. The results 
from our study demonstrate that in conjunction with the RING domain of Hakai, 
dimerization of Hakai through the formation of the atypical ZnF creates a novel pTyr-
binding domain, called the HYB domain. Originally postulated to recognize multiple 
consecutive phosphotyrosines, it was instead found that the HYB domain recognizes a 
single phosphotyrosine residue flanked by acidic amino acids. Interestingly, this may 
indicate a bias toward Src substrates because Src kinase has a preferred, but not strict, 
recognition sequence of Y(p)-E-E-I/V (Yeatman, 2004). 
 
The zinc-coordinating residues of each Hakai monomer consist of a conserved series 
of nine cysteine and three histidine residues that facilitate Hakai dimerization. Based 
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on sequence analysis, LNX1 and LNX2 also harbor such a sequence motif, although 
the last conserved histidine is replaced by cysteine. While the full structures of the 
LNX proteins are currently unknown, it is possible that, based on sequence homology, 
they also contain the HYB domain. As the HYB domain contains a RING domain, its 
occurrence would be predominantly in E3 ubiquitin ligases, which has implications in 
the way these proteins recognize their targets and effect downstream signaling.  
 
Although the zinc-coordinating residues within the ZnFs of the HYB domain are 
critical, the protein folding of the primary sequences surrounding the cysteine and 
histidine residues are also important in defining its characteristics. This chelation-
derived folding provides the necessary three-dimensional structure while specific 
amino acids within the sequences between the zinc-coordinating residues are 
instrumental in recognizing and binding phosphorylated tyrosines of target proteins. 
In the case of Hakai, four residues were identified through NMR studies to bind to E-
cadherin, H127, Y176, H185 and R189. It is noteworthy that there is strict 
conservation of these residues between Hakai and ZNF645. On the other hand, the 
differences in their binding targets are most likely dictated by amino acids that are not 
common to both proteins, although this aspect requires further study. It would also be 
interesting to observe if LNX1 or LNX2 binds phosphorylated tyrosine residues. 
Based on sequence homology, both LNX1 and LNX2 harbor most of the zinc-
coordinating residues of the HYB domain. However, only LNX2 has the equivalent of 
R189 of Hakai. Neither of the LNX proteins has the equivalent of Y176. It is possible 
that these two proteins bind a different set of tyrosine-phosphorylated proteins by 
utilizing different residues within their sequences. Thus while the basic sequence 
required to provide a unique pTyr-binding structure is apparent within the four 
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proteins, a number of questions regarding the exact pTyr-binding requirements of 
these proteins remain unanswered. 
 
In conclusion, we have identified a novel HYB domain, made up of two structurally 
atypical ZnF domains, which recognize a previously unidentified phosphotyrosine 
motif. Our structural data indicate that the HYB domain forms a positively charged 
pocket, implying that it represents a highly suitable drug target. As dysfunctional E3 
ubiquitin ligases are often associated with diseases (Burger et al., 2006; Lohr et al., 
2010), the presence of the HYB domain in these proteins offers a specific target for 
directed therapies. 
 
To summarize, this chapter described the discovery of a novel pTyr-binding domain, 
the HYB domain, which bears a dimeric fold. This is in contrast to the existing pTyr-
binding domains, typified by SH2 and PTB domains, which generally function as 
monomer. In the next chapter, we have designed a C-terminal deletion mutant of the 
HYB domain, HYBΔC, which exists as a monomer in solution. Further, we have 
studied the pTyr-binding property of HYBΔC. 
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CHAPTER III 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Dimeric switch of Hakai-truncated monomers during 





3.1 Introduction 	  
Phosphotyrosine (pTyr) binding domains are key determinants of specificity and 
selectivity in many signal transduction pathways and act by integrating pTyr signals 
from upstream kinases to downstream effectors that regulate the complex physiology 
of eukaryotic cells (Deribe et al., 2010; Hunter, 2009; Yaffe, 2002). The SH2 domain 
was the first pTyr-binding domain to be discovered (DeClue et al., 1987; Sadowski et 
al., 1986), and has since been extensively characterized (Filippakopoulos et al., 2009; 
Forman-Kay and Pawson, 1999; Liu et al., 2006; Pawson and Nash, 2003; Songyang 
et al., 1993; Yaffe, 2002). The second domain to be identified with a capacity to bind 
tyrosine residues was the Phosphotyrosine Binding (PTB) domain (Kavanaugh and 
Williams, 1994). Subsequently, idiosyncratic pTyr-binding domains have been 
observed in the C2 domain of Protein Kinase C δ (Benes et al., 2005) and Pyruvate 
Kinase M2 (Christofk et al., 2008), and we recently reported the existence of a third 
pTyr-binding domain in Hakai and coined it the HYB domain for Hakai 
phosphotyrosine binding (Mukherjee et al., 2012). 
 
Hakai is an E3 ubiquitin ligase first noted for its role in regulating E-cadherin 
expression and disrupting cell-cell contacts in epithelial tissues (Fujita et al., 2002; 
Pece and Gutkind, 2002). Subsequent work has identified an upregulation of Hakai in 
human colon and gastric adenocarcinomas (Abella et al., 2012; Figueroa et al., 2009). 
The HYB domain interacts with other Src substrates, such as Cortactin, a structural 
protein involved in coordinating actin rearrangement during cell movement (Wu et 
al., 1991), and DOK1, a scaffolding protein that assists in the assembly of signalling 
complexes (Mashima et al., 2009). Both of these proteins have important functional 
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contributions in the progression of cancer (Noh et al., 2013; Siouda et al., 2012), and 
both are regulated by the activity of Hakai (Mukherjee et al., 2012). The novel 
features of the HYB domain and its interaction with various key molecules may 
indicate a physiologically important role for Hakai in cancer.  
 
The HYB domain comprises amino acids 106-206, and forms an atypical, zinc-
coordinated homodimer in an antiparallel, intertwined configuration, utilizing 
residues from the phosphotyrosine-binding region of two Hakai monomers. The 
dimeric nature of the domain configures the formation of a phosphotyrosine-binding 
pocket that recognizes specific phosphorylated tyrosine residues and flanking acidic 
amino acids of its substrates (Mukherjee et al., 2012). The C-terminal region, which 
harbors the atypical zinc-coordination motif and key residues involved in the pTyr 
interaction, plays a key role in the dimerization observed in the HYB domain. In the 
present study, we investigated the consequences of deleting residues from the C-
terminus of Hakai whilst maintaining the key residues involved in the pTyr 
interaction and the atypical zinc-coordination of the E3 ligase. Through this structural 
truncation, we identified a C-terminal deletion mutant, Hakai (aa 106-194), herein 
referred to as HYBΔC, which exists as a monomer in solution and flips to a dimeric 
arrangement in the presence of a pTyr substrate, with the incoming substrate inducing 
the conformational changes required to initiate dimerization of HYBΔC monomers. 
This monomeric to dimeric switch of HYBΔC in the presence of the phosphorylated 
substrate was further validated by biophysical and solution studies. Taken together, 
our results suggest that the dimerization of Hakai pTyr-binding domain is a unique 
prerequisite for substrate binding.  
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3.2 Materials and Methods 	  
3.2.1 Protein expression and purification 
  
Inserts corresponding to Hakai (amino acids 106-194) have cloned into pGEX-6P-1 
vector (GE Healthcare) using BamHI and SalI as the restriction sites and expressed as 
a GST-fusion protein in E. coli BL21 (DE3) cells. The cells were cultured in Luria 
Broth medium at 37°C until the A600 nm reached 0.6–0.7, IPTG and zinc sulphate 
were then added at concentrations of 0.15mM and 50µM, respectively, and growth 
continued for around 20 hours at 15°C. Cells were harvested by centrifugation (8000 
× g, 10 min, 4°C), and the pellet was resuspended in lysis buffer (50 mM Bis-Tris pH 
6.5, 300mM NaCl, 10µM zinc chloride, 5% Glycerol, 0.5% Triton-X 100, 2mM DTT, 
1mM phenylmethylsulfonylfluoride (PMSF) and homogenized using a French Press 
Cell Disrupter (Thermo Electron Corporation). Subsequently, the cell lysate was 
centrifuged at 18,000 rpm for 30 min at 4°C (JA-25.50 fixed angle rotor, Beckman 
Coulter centrifuge) and the supernatant was allowed to bind to glutathione-sepharose 
resin (GE Healthcare) for 2-4 hours at 4°C and was subsequently washed with a 
buffer containing 50 mM Bis-Tris pH 6.5, 300mM NaCl, 5% glycerol, 2mM DTT. 
After the washing step, an overnight on-column cleavage at 4°C with GST-
PreScission Protease (GE Healthcare) was performed to remove the GST tag. A major 
portion of GST and GST-PreScission Protease remained bound to the glutathione-
sepharose resin and the flow-through containing the partially purified, untagged 
proteins were further purified using a Superdex 75 size exclusion column (GE 
Healthcare) equilibrated with a buffer containing 50mM sodium phosphate buffer pH 
6.5 and 5mM DTT. 
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3.2.2 NMR spectroscopy  	  
All NMR experiments were carried out at 25 °C on a Bruker Avance 800 MHz 
spectrometer equipped with a TXI cryogenic probe. 1H, 13C, and 15N resonance 
assignments were performed by measuring the three-dimensional HNCACB, three-
dimensional CBCA(CO)NH (Bax and Grzesiek, 1993), and three-dimensional CCH-
TOCSY (Fesik et al., 1990) spectra. Inter-proton distance restraints for structural 
calculation were obtained from three-dimensional 13C-edited NOESY-HSQC, three-
dimensional 15N-edited NOESY-HSQC, and two-dimensional NOESY spectra using a 
100-ms mixing time. 1DNH residue dipolar couplings were measured using the IPAP 
method (Ottiger et al., 1998). The residue dipolar coupling values were obtained by 
subtracting the reference value in isotropic solution. Two- and three-dimensional 
NMR spectra were processed using the NMRPipe program (Delaglio et al., 1995), and 
data analysis was performed with the help of the Sparky program (Goddard and 
Kneller, 2004). 
 
The structure was calculated using the Xplor-NIH 2.24 software package (Schwieters 
et al., 2003). A total of 1014 NOE distance restraints, 21 hydrogen bonds, and 110 
dihedral angle restraints were predicted by the TALOS program (Cornilescu et al., 
1999). Residue dipolar couplings were used in the final cooling stage. 100 structures 
were calculated using 30,000 steps of simulated annealing, and a final ensemble of 20 






3.2.3 Size-exclusion chromatography 
 
HYBΔC protein samples, with concentrations at A280 nm of 1.0, in the absence or 
presence of phosphorylated E-cadherin749–761 peptide, was applied to a Superdex 75 
size-exclusion column (GE Healthcare) equilibrated using in buffer containing 50mM 
sodium phosphate pH 6.5 and 5mM DTT and pre-calibrated using a gel-filtration 
standard (Bio-Rad). 
 
3.2.4 Circular Dichroism spectrometry 	  
Far UV spectra (260–190 nm) of HYBΔC and HYB were measured using a Jasco J-
810 spectropolarimeter in phosphate buffer (pH 6.5) at room temperature using a 0.1-
cm path length and stoppered cuvettes. Six scans were recorded, averaged and the 
baseline subtracted. 
 
3.2.5 Dynamic light scattering 	  
Dynamic light scattering studies were carried out on a DynaPro Light Scattering 
instrument (Protein Solutions, USA) with protein concentrations at A280 nm of 1.0, in 
buffer containing 50mM sodium phosphate pH 6.5 and 5mM DTT. 
 
3.2.6 Isothermal Titration Calorimetry 	  
Phosphorylated peptide of E-cadherin (residues 749–761) was titrated at a molar 
concentration of 575 µM against 75 µM of HYBΔC in a VP-ITC microcalorimeter 
(Microcal, Northhampton, UK) at 293 K. 30 titrations were carried out using 10-	  µl 
injections of the peptide into the sample cell containing HYBΔC and the data were 
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analysed with a single-site binding model using the Origin software package v7.0 
supplied by Microcal. All measurements were repeated thrice. 
 
3.2.7 Analytical Ultracentrifugation (AUC) 
 
The oligomeric states of the HYBΔC in the absence and presence of pTyr-peptide was 
investigated by monitoring their sedimentation properties in the AUC sedimentation 
velocity experiments. 400 µl of samples at A280 nm of 1 in 50mM Sodium Phosphate 
pH 6.5 and 5 mM DTT were used. Sedimentation velocity profiles were collected by 
monitoring the absorbance at 280 nm. The samples were centrifuged at 40,000 rpm at 
25 °C in a Beckman ProteomeLab XL-I centrifuge fitted with a four-hole AN-60 Ti 
rotor and double-sector aluminum centerpieces and equipped with absorbance optics. 
The scans were analyzed using the Sedfit program (Brown and Schuck, 2006). 
 
3.3 Results  	  
3.3.1 HYBΔC is a monomer in solution 
 
We previously demonstrated that the HYB domain consists of an atypical zinc-
coordinated, intertwined homodimer formed by an anti-parallel arrangement of two 
Hakai (aa 106–206) monomers (Mukherjee et al., 2012). The dimerization mainly 
occurs through the C-terminal region of Hakai (aa 106-206), which harbors key pTyr-
interacting residues as well as the atypical zinc-coordination motif formed by two 
histidine residues (H185 and H190) and one cysteine residue (C172) from one 
monomer and a second cysteine residue (C166) from the adjacent monomer. In this 
study, we expressed and purified a C-terminal deletion mutant comprising residues 
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106-194, herein referred to as HYBΔC, which retains all of the residues involved in the 
atypical zinc-coordinated motif and the pTyr interaction. The gel-filtration elution 
profile showed that HYBΔC had an apparent molecular weight equivalent to a 
monomeric subunit (Figure 3.1). Further, the monomeric nature of HYBΔC was 
verified using AUC analysis, which showed a peak corresponding to an apparent 
molecular weight of monomeric HYBΔC (~10,200 Da) (Figure 3.2). The dynamic light 
scattering experiments also revealed an apparent molecular weight of monomeric 
HYBΔC. The dynamic light scattering experiments also revealed an apparent 
molecular weight of the monomeric HYBΔC (Figure 3.3).  
 
 
Figure 3.1 Gel Filtration Profile of HYBΔC. HYBΔC was loaded onto a calibrated 
Superdex-75 gel filtration chromatography column. The elution profile suggests that 
HYBΔC exists as a monomer. The SDS-page of HYBΔC depicts the purity and the 







Figure 3.2 Analytical ultracentrifugation (AUC) analysis of HYBΔC. The monomeric 
nature of HYBΔC was studied using sedimentation velocity analysis. The 
sedimentation velocity profiles were collected by monitoring the absorbance at 280 
nm as the samples with concentrations at A280 nm of 1.0 were centrifuged in a four-
hole AN-60 Ti rotor at 40,000 rpm at 25 °C. The scans were analyzed using Sedfit 
program (Brown and Schuck, 2006) to obtain the molecular mass profile of HYBΔC 
which indicates that the protein exists as a monomer in solution with an apparent 





Figure 3.3 DLS studies performed for HYBΔC. The DLS readout of HYBΔC with 
concentration at A280nm of 1.0 shows an apparent molecular weight close to the 
monomeric HYBΔC. The apparent molecular weight is highlighted by a red box. 	  	  
3.3.2 Circular dichroism indicates conformational changes in HYBΔC in the 
presence of substrate 	  
Circular dichroism (CD) analysis revealed significant differences in the secondary 
structure composition between the monomeric HYBΔC and the dimeric HYB domain 
(Figure 3.4). In the presence of the phosphorylated peptide of E-cadherin, 
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corresponding to residues 747-760, the CD spectra demonstrated conformational 
changes to the HYBΔC (Figure 3.4). These significant differences in the conformation 
of HYBΔC in the CD spectral analysis motivated us to determine the NMR structure of 
HYBΔC to understand the structural basis of this ligand-associated conformational 
change.  
 
Figure 3.4 Circular Dichroism analyses revealed differences between HYBΔC and 
HYB. Circular dichroism analysis shows a significant difference in the secondary 
structure composition between HYBΔC and HYB domain. Furthermore, in the 
presence of the phosphopeptide ligand (E-cadherin747-760), the CD spectrum of HYBΔC 
shows marked resemblance with that of the HYB domain, suggesting a 
conformational change in HYBΔC in the presence of ligand.  
 
3.3.3 NMR structure of HYBΔC 	  
In order to gain structural insights into the tertiary fold of HYBΔC, we solved its 
solution structure by NMR. The NMR structure of HYBΔC was refined to a final 
RMSD of 1.42 ± 0.44 Å (backbone) (Table 3.1) for the 20 best structures (Figure 3.5 
and Figure 3.6). The NMR structure of HYBΔC reveals a monomeric fold, which 
contains a N-terminal RING domain and a C-terminal zinc co-ordination domain 
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bearing a C2H2-type zinc finger (ZnF) configuration (Figure 3.6 and 3.7). As 
expected, the solution structure of HYBΔC contains three Zinc co-ordination sites 
(Figure 3.6 and 3.7). The RING domain (residues 106-148) adopts a typical RING 
architecture containing two β-strands (β1 and β2) and one α-helix (α1), which engage 
two Zinc ions (Figures 3.6 and 3.7). The C-terminal domain (residues 148-194) lies in 
close association with the N-terminal RING domain by means of the third β-strand, 
β3, which forms an anti-parallel β-sheet arrangement with β1 and β2 of the RING 
domain (Figure 3.6 and 3.7). The C-terminal domain contains the third Zinc co-
ordination site of HYBΔC, which is formed by the residues C166, C172, H185 and 
H190, resembling a C2H2-like ZnF (Figure 3.7), with the two cysteines (C166 and 
C172) forming a hairpin-loop and the two histidines (H185 and H190) lying on the 
α-helix (α2).  
 
The overall structure of HYBΔC was compared with other proteins present in the 
Protein Data Bank (PDB) using the DALI server 
(http://ekhidna.biocenter.helsinki.fi/dali_server) (Holm et al., 2008). The DALI server 
showed around 230 structural homologues, all of which contain a RING domain fold 
like HYBΔC, but no structural resemblance beyond the RING domain (Table 3.2). In 
order to identify if any protein has a fold similar to the C-terminal region of HYBΔC 
that contains the C2H2-ZnF, a DALI search was performed for the localized fold 
comprising of the amino-acid residues 159-194 of HYBΔC. The DALI results showed 
that there are only 4 proteins, which contain a fold similar to the C2H2-ZnF of 
HYBΔC (Table 3.3). Interestingly, none of these proteins contain a RING domain. 
Thus, the structural analysis using DALI clearly indicates that the combination of the 
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N-terminal RING domain and the C-terminal region containing the C2H2-ZnF 
produces a novel fold in HYBΔC. 
Parameters  
All NOE distance restraintsa  1014 
    Intra-residue 240 
          Sequential (׀i–j׀ = 1) 333 
          Medium-range ( 1 <׀i–j׀≤5) 197 
          Long-range (׀i–j׀≥5) 244 
Hydrogen bonds restraints 21 
Dihedral angle restraints(φ, ψ )b 110 
Deviations from idealized covalent geometryc  
   RMSD of bond lengths (Å) 0.0026±0.0026 
   RMSD of bond angles (°) 0.3844±0.0224 
   RMSD of improper angles (°) 0.3272±0.0182 
Deviations from experimental restraints  
   RMSD of distance restraints (Å) 0.0472±0.0021 
   RMSD of dihedral angle restraints (°) 0.2363±0.048 
Ramachandran plot analysis (%)d  
   Residues in allowed region 94.4% 
   Residues in generally allowed regions 5.1% 
   Residues in disallows disallowed regions 0.5% 
Average RMSD from mean structure (Å)e  
   All residues 1.42±0.44 
   Regular 2° structure region 0.76±0.33 
 
Table 3.1 NMR data and structure determination details for HYBΔC 
a  The distance restraints were obtained by classifying the NOE cross peaks into      three 
categories: strong (1.8–2.9 Å), medium (1.8–3.5 Å), and weak (1.8–5.0 Å). Solution 
structures of Hakai was calculated using the torsion angle dynamics simulated annealing 
method within XPLOR-NIH(Schwieters et al., 2003).  
b  Dihedral angles of backbone ϕ and ψ were predicted by TALOS (Cornilescu et al., 1999) 
using the chemical shifts of Cα, Cβ, Hα, N, and HN. 
c  Twenty lowest-energy conformers with no NOE violations greater than 0.3 Å and no 
torsion angle violations greater than 3° were selected from 100 conformers to represent 
the NMR ensembles. 
d     Calculated with PROCHECK-NMR (Laskowski et al., 1996). 






Figure 3.5 3D NMR structure of HYBΔC. Superposition of 20 energy-minimized 





Figure 3.6 Ribbon diagram of the lowest energy conformer representing the 3D NMR 
structure of HYBΔC. Each monomer contains three zinc coordination sites- Site 1, Site 




Figure 3.7 Metal co-ordinations in the NMR structure of HYBΔC. The coordination of 





Table 3.2 Structural comparison of HYBΔC domain with structural homologs. 
Representative structural matches of the HYBΔC searched in the PDB using DALI 






Table 3.3 Structural comparison of HYBΔC(amino acid residues 159-194) domain 
with structural homologs. Representative structural matches of the HYBΔC (amino 
acid residues 159-194) searched in the PDB using DALI server (Holm et al., 2008). 
 
3.3.4 Comparison of the structure of HYBΔC with HYB domain 	  
In order to analyze the structural differences between monomeric HYBΔC with HYB 
domain, HYBΔC was superposed onto one of the Hakai (aa 106-206) monomeric 
counterparts present in the HYB domain. The structural segment corresponding to 
residues 106-166 of HYBΔC and a monomer equivalent of the HYB domain fold in a 
similar manner with a RMSD of 0.9 Å (Figure 3.8C). This implies that the RING 
domain (residues 106-148) and linker sequence (residues 149-166) fold exactly in a 
similar manner in both HYBΔC and the monomer equivalent in the HYB domain. The 
structural differences arise beyond Cys166, which comprises the C–terminal zinc co-
ordination site (Site 3) and the terminal α-helix (α2) (Figure 3.8). The C-terminal 
helix α2 of HYBΔC flips by 180° and is separated from the α2 of HYB monomeric 
counterpart by 25 Å distance (Figure 3.8C and 3.8D). Furthermore, the comparison of 
HYBΔC with the dimeric HYB domain clearly reveals a structural rearrangement, 
which arises due to systematic reshuffling among the zinc-coordination residues to 
engage the zinc ion in the C-terminal region of the monomeric and dimeric 
conformers, respectively (Figure 3.9). In HYBΔC, the four zinc-coordination residues 
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forms a C2H2-ZnF, with all residues situated on the same monomeric chain, which is 
distinct from the atypical zinc-coordination motif present in HYB domain that is 
formed by sharing of the zinc ions between two monomers (Figure 3.9). Thus, the 
NMR structure provides the basis for the existence of HYBΔC as a monomer in 
solution, bearing a different fold, with the reason being the replacement of the 
atypical zinc-binding motif, which is critical for the dimeric fold of HYB, by a C2H2-




Figure 3.8 Comparison of the monomeric HYBΔC (shown in green) with the Hakai 
(aa 106-206) monomeric counterpart (shown in yellow) of the dimeric HYB domain. 
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(A) and (B) Ribbon representations of HYBΔC and Hakai (aa 106-206) monomeric 
counterpart (pdb code: 3vk6) of HYB domain shown respectively, in the same 
orientation.  (C) Superposition of HYBΔC on Hakai (aa 106-206) (pdb code: 3vk6) 
reveals that the stretch of residues from 106-166, which contains the RING domain 
and a part of the C-terminal domain in both structures overlap with a rmsd of 0.9	  Å. 
The differences arise after C166 highlighted by red dotted circle. Beyond this point, 
the folds of HYBΔC and HYB monomeric counterpart is completely different, with the 
helix α2 flipping by 180° and separated by around 25 Å with respect to each-other. 
(D) The conformational changes in the structures of HYBΔC and Hakai (aa 106-206) 




Figure 3.9 Comparison of the monomeric HYBΔC with the HYB domain (pdb code: 
3vk6) that contains a dimeric fold containing paired Hakai (aa 106-206) monomers. 
The monomeric fold of HYBΔC (shown in green) contains a C2H2-ZnF in the C-
terminal domain, highlighted by dotted circles (A) in which all the four zinc 
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coordinating residues are situated in the same monomeric chain. On the other hand, 
the dimeric fold of HYB domain is formed by the sharing of two zinc ions between 
the Hakai (aa 106-206) monomers, shown by two dotted circles in (B), such that three 
of the four zinc-binding residues come from one monomer while the fourth residue 
comes from the adjacent monomer. The two monomers of Hakai (aa 106-206) in (B) 
are colored as yellow and cyan, with one monomer shown in ribbon representation 
while the other monomer is shown as Cα trace for clarity. The zinc-coordinating side-
chains are shown as sticks, and color-coded according to the color of the monomer on 
which they lie. (C) and (D) The schematic representation of the difference in the 
monomeric fold of HYBΔC and the dimeric fold of HYB domain containing paired 




Figure 3.10 Topology of HYBΔC (A) is compared with that of HYB domain (pdb 
code: 3vk6) (B). The zinc ions are shown as spheres (color coded according to the 
monomer colors) and the three-zinc coordination sites are indicated for each monomer 
in both A and B. Each monomer consists of three Zinc coordination sites. In HYBΔC, 
four zinc-coordination residues, all situated on the same monomer form the Site 3; 




3.3.5 HYBΔC binds phospho-E-cadherin747-760 as a dimer 
 
We next questioned if the monomeric HYBΔC can still engage the pTyr ligand. Our 
earlier studies showed HYB as a dimeric fold interacts with pTyr ligands (Mukherjee 
et al., 2012). Hence, we conducted isothermal titration calorimetry (ITC) experiments 
to investigate the binding property of HYBΔC with the peptide ligand corresponding to 
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our previously established pTyr motif of E-cadherin, which contains the E-cadherin 
residues (747-760) (Mukherjee et al., 2012). The ITC experiment revealed that 
HYBΔC binds with the pTyr ligand of E-cadherin with a binding stoichiometry of 2:1 
[HYBΔC: pTyr ligand] and an affinity of 3.7µM Kd (Figure 3.11). This indicates that 
phospho-E-cadherin747-760 ligand interacts with a dimeric form of HYBΔC. 
 
Figure 3.11 Binding studies of HYBΔC with phospho-E-cadherin747-760 using ITC. The 
tyrosine phosphorylated E-cadherin747-760 was titrated against HYBΔC using ITC. The 
top panels show the heat release profiles after baseline correction and the lower panels 
indicate the binding isotherms for the interactions. The dissociation constant (Kd) and 
binding stoichiometry (N) is shown in the table. 
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To further probe the dimeric state of HYBΔC in the presence of the phospho-E-
cadherin747-760 ligand, HYBΔC was separated on a calibrated gel-filtration column in 
the presence and absence of the ligand. The comparison of the gel-filtration elution 
profiles in the presence and absence of the phospho-E-cadherin747-760 ligand show that 
HYBΔC elutes as a dimer in the presence of the ligand and as monomer in its apo form 
(Figure 3.12).  
 
 
Figure 3.12 Comparison of gel filtration profiles of HYBΔC in the presence and 
absence of pTyr ligand (phospho-E-cadherin747-760). HYBΔC was loaded onto a 
calibrated Superdex-75 gel filtration chromatography column in the presence and 
absence of the pTyr ligand. The elution profile suggests that HYBΔC exists as a dimer 
in the presence of ligand whereas; it exists as a monomer in the absence of the ligand. 
 
In order to further verify the ligand-induced dimerization of HYBΔC, sedimentation 
velocity AUC experiments were conducted with the samples containing HYBΔC in the 
presence of phospho-E-cadherin747-760 peptide. From analysis of the AUC data using 
Sedfit (Brown and Schuck, 2006), the apparent molecular weight of HYBΔC in the 
presence of ligand is 20000Da (Figure 3.13), which is equivalent to the twice the 
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monomeric molecular weight of HYBΔC determined by AUC in the absence of the 
ligand (Figure 3.2). Additionally, the formation of HYBΔC dimer in the presence of 
ligand is also supported by the results obtained through dynamic light scattering, 
which show an apparent molecular weight of corresponding to the dimer (Figure 
3.14). The combined results suggest that HYBΔC switches from a monomeric 
conformation to a dimeric form in the presence of the pTyr-containing ligand. 
 
Figure 3.13 AUC analysis of HYBΔC in the presence of phospho-E-cadherin747-760 
ligand. The ligand-induced dimerization of HYBΔC was studied using by 
sedimentation velocity analysis. The sedimentation velocity profiles were collected by 
monitoring the absorbance at 280 nm as the samples with concentration at A280 nm of 
1.0 were centrifuged in	  a four-hole AN-60 Ti rotor	  at 40,000 rpm at 25 °C. The scans 
were analyzed using Sedfit program (Brown and Schuck, 2006) to obtain the 
molecular mass profile of HYBΔC in the presence of the ligand. The results clearly 
indicate that the protein exists as a dimer in the presence of the ligand with an 
apparent molecular weight of 20000Da. 	  
	  
Figure 3.14 DLS studies performed for HYBΔC in the presence of phospho-E-
cadherin747-760 ligand. DLS was carried out with HYBΔC protein samples with 
concentration at A280nm of 1.0. The DLS readout indicates that HYBΔC exists as a 
dimer in solution in the presence of ligand. 
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3.4 Discussion 	  
Phosphotyrosine binding domains are critical, modular components that bind to 
phosphorylated tyrosine residues in acceptor proteins to create multi-protein 
complexes and regulate several intracellular signalling pathways (Evans et al., 2012; 
Pawson and Nash, 2003; Yaffe, 2002). Dysregulation of these pathways is often 
associated with oncogenic transformation (Pawson, 2002), rendering pTyr-binding 
domains as attractive targets for directed therapies (Burke et al., 2001; Machida and 
Mayer, 2005b; Sawyer et al., 2002). So far, all of the major pTyr-binding domains, 
including SH2 and PTB domains, tend to be monomeric (Liu et al., 2006; Stein et al., 
2003), barring the few exceptions where they function as homodimers. These 
exceptions include the SH2 domains of Grb10, Grb14, Grb7, APS, and SH2-B 
(Depetris et al., 2005; Hu and Hubbard, 2005; Liu et al., 2006; Stein et al., 2003). In 
addition, in STAT proteins, tyrosine phosphorylation-mediated dimerization has been 
reported to occur via SH2 domains (Darnell, 1997; Soler-Lopez et al., 2004; Wenta et 
al., 2008). The recently identified pTyr-binding fold in Hakai, HYB, bears a novel 
dimeric fold consisting of two atypical ZnFs shared between the paired Hakai (aa 
106-206) monomers that exist in an intertwined configuration across the flexible C-
terminal regions (Mukherjee et al., 2012). In this study, we showed that the deletion 
of flexible C-terminal residues of HYB induces a monomeric fold in solution. A 
similar observation was recently reported in the C-terminal domain of SARS-CoV 
main protease (Mpro-C ), where the truncation of the disordered C-terminal helix results 
in transition from dimer to monomer (Kang et al., 2012). In yet another study, 
dimer/tetramer equilibrium observed in Escherichia coli DNA mismatch repair 
(MMR) protein MutS is converted into a monomer/dimer equilibrium upon deletion 
of the C-terminal 53 amino acids (Manelyte et al., 2006).  
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In order to understand the structural basis for this monomeric conformation of 
HYBΔC, we determined its solution NMR structure. The NMR structure revealed that 
the characteristic atypical ZnF, which plays a key role in the dimeric fold of the HYB 
domain, is replaced by a C2H2-type ZnF in HYBΔC, formed by two cysteines and two 
histidines, all situated on the same monomer. This represents a unique monomeric to 
dimeric switching mechanism.  
 
One of the best studied physiological functions of the HYB domain is its interaction 
with and regulation of the tyrosine phosphorylated E-cadherin at cell junctions (Fujita 
et al., 2002; Ishiyama and Ikura, 2012; Ishiyama et al., 2010; Mukherjee et al., 2012). 
As such, we selected a tyrosine phosphorylated E-cadherin747-760 peptide as a model 
substrate to further assess this monomeric conformation of HYBΔC and to determine if 
it is still functional. The ITC interaction studies showed that the ligand binds with the 
protein only in its dimeric form. This result is consistent with our previous studies that 
a dimeric HYB fold is necessary to create the pTyr-binding pocket, which was also 
validated with full-length Hakai in cell-based experiments (Mukherjee et al., 2012). A 
series of solution studies further validated this switch to a dimeric conformation of 
HYBΔC in the presence of the tyrosine phosphorylated E-cadherin747-760 ligand. 
Previous studies have demonstrated ligand-mediated dimerization as a novel 
mechanism for protein-carbohydrate recognition (Flint et al., 2004; Sanchez-Vallet et 
al., 2013). The present study extends this paradigm to pTyr-signaling and regulation 
in Hakai.  
 
In conclusion, we have identified a novel monomeric fold of HYBΔC, which impairs 
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its pTyr binding property. However, in the presence of the pTyr ligand, the 
monomeric HYBΔC becomes a dimer in order to create the pTyr-binding pocket to 
engage the substrate. The findings from this study suggest that the dimeric 
architecture of the HYB domain is necessary to engage the pTyr-ligand, which is in 
sharp contrast to all the other known pTyr-binding domains, which mainly function as 
monomers. Selectively targeting the dimeric interface of therapeutically important 
enzymes has emerged as an attractive method of allosteric inhibition (Andreola, 2009; 
Huber et al., 2012; Lebon and Ledecq, 2000; McMillan et al., 2000). The importance 
of the dimeric architecture of HYB in pTyr substrate binding demonstrated by the 
present study makes it an ideal target for designing selective allosteric inhibitors that 
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4.1 Conclusions 	  
Prior to our studies, SH2 and PTB domains were the only two major pTyr-binding 
domains known to exist, apart from the idiosyncratic cases exemplified by the C2 
domain of PKCδ and the M2 isoform of Pyruvate Kinase. When SH2 domain was 
discovered about 25 years ago, only 26 proteins were thought to contain SH2 domain. 
At present, around 111 human proteins have been found to bear a SH2 domain. 
Similarly, at the time of discovery of PTB domain in 1994, 6 PTB domain-containing 
proteins were identified, but over the time, more PTB domains have been discovered 
and presently around 54 PTB domains have been identified in human genome. After a 
span of more than 18 years, we have discovered a novel pTyr-binding domain in 
Hakai, and named it as the HYB domain. In the case of HYB, we have identified that 
it exists across numerous species, ranging from drosophila to human, with at least 4 
unique human proteins sequences known to-date. This makes HYB domain the third 
major pTyr-binding domain after SH2 and PTB domains, which were so far, the only 
major pTyr-binding domains known to exist. All the HYB homologous protein 
sequences identified across the numerous species contain the highly conserved 9 
cysteines and 3 histidines that contribute to the metal co-ordination, dimerization and 
to maintain the fold. Thus all these proteins are expected to bear the unique HYB fold. 
As was the case with SH2 and PTB domains, with more research, it is expected to 
discover more proteins, which bear the HYB fold. Moreover, the HYB fold has no 
resemblance with any of the known 75,000 structures in the protein data bank. The 
novel features of the Hakai pTyr-binding domain guarantee a novel-binding mode 
with the substrate proteins with which it binds in a pTyr-dependent manner. 
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Having discovered a novel pTyr-binding structure in Hakai, we next sought to study 
its binding mechanism with the pTyr-motif of E-cadherin. One of the novel features 
of the pTyr-motif of E-cadherin was the presence of three consecutive Tyrosine 
residues. Earlier studies by Fujita et al. in 2002, suggested that the first two tyrosine 
residues where important for binding with Hakai in a phosphotyrosine dependent 
manner. However, there were no comprehensive studies, which evaluated the relative 
importance of the three-tyrosine residues independently and in combination. We 
identified that a single phosphotyrosine residue of E-cadherin is most critical and can 
bind independently of remaining two tyrosines present in the binding motif of E-
cadherin. In addition, we show that the acidic residues that flank the central 
phosphotyrosine are critical for binding with Hakai pTyr-binding domain. The NMR 
and mutational studies revealed that both the RING domain, the minimum 
phosphotyrosine binding region, as well as dimerization, seen in the structure of 
Hakai (aa 106-206) are important for recognizing the pTyr-containing motifs. We 
demonstrated that in conjunction with the RING domain, dimerization of Hakai 
through the minimum pTyr-binding region leading to the formation of the atypical 
ZnF creates a novel HYB domain. Furthermore, using mass spectrometry, we 
experimentally identified around 30 novel Src substrates that are targeted by the HYB 
domain. Out of these new HYB binding proteins that we discovered, we chose two 
candidates, viz. Cortactin and DOK1, and further characterized their interaction with 
HYB domain using biophysical and cell-based methods.  
 
In addition, we show that ZNF645 possesses a HYB domain but demonstrates 
different target specificities. In an additional study, we also demonstrated that the 
deletion of the C-terminal residues from the HYB domain results in a monomeric 
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form. However, this monomeric form switches into a dimer in the presence of 
phospho-E-cadherin peptide in order to interact with the pTyr- motif. This study 
further confirms that dimerization is absolutely essential for the pTyr-binding 
property of the HYB domain.   
 
4.2 Future directions 	  
The present study provides key insights into the nature and substrate binding 
mechanism in the novel pTyr-binding domain present in Hakai. Furthermore, we have 
experimentally validated the pTyr motif that represents the minimum interacting 
regions present in E-cadherin, Cortactin and DOK1 and binds with the HYB domain 
with substantial affinity. This forms the basis for carrying out the co-crystallization 
studies of HYB domain with the minimum interacting regions of E-cadherin, 
Cortactin and DOK1. Since the interactions of Hakai with E-cadherin, cortactin and 
DOK1 are physiologically important and implicated in various cancer and diseased 
conditions, the novel structural features of co-crystal structures will open new 
avenues for therapeutic interventions. Based on the co-crystal structures of HYB- 
substrate complexes, small molecule inhibitors can be designed to selectively break 
these interactions, which may be used as directed therapies towards specific types of 
cancer that involve such interactions. 
 
In addition to Cortactin and DOK1, we have also identified around 30 binding 
partners for HYB domain, many of which represent adaptors, kinases, phosphatases, 
and regulators of small GTPases, which play crucial roles in cell signaling. In future, 
we propose to further investigate the binding mechanism of the HYB domain with 
these important targets. 
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Furthermore, ZNF645 possesses a HYB domain but demonstrates different target 
specificities, as it can bind tyrosine phosphorylated E-cadherin, but not Cortactin. 
Therefore, it would be of great interest to study the structural and mechanistic aspects 
of the HYB domain of ZNF645, in order to understand the determinants of substrate 
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Phosphotyrosine-binding domains, typified by the SH2
(Src homology 2) and PTB domains, are critical upstream
components of signal transduction pathways. The E3 ubi-
quitin ligase Hakai targets tyrosine-phosphorylated E-cad-
herin via an uncharacterized domain. In this study, the
crystal structure of Hakai (amino acids 106–206) revealed
that it forms an atypical, zinc-coordinated homodimer
by utilizing residues from the phosphotyrosine-binding
domain of two Hakai monomers. Hakai dimerization al-
lows the formation of a phosphotyrosine-binding pocket
that recognizes specific phosphorylated tyrosines and
flanking acidic amino acids of Src substrates, such as E-
cadherin, cortactin and DOK1. NMR and mutational ana-
lysis identified the Hakai residues required for target
binding within the binding pocket, now named the HYB
domain. ZNF645 also possesses a HYB domain but demon-
strates different target specificities. The HYB domain is
structurally different from other phosphotyrosine-binding
domains and is a potential drug target due to its novel
structural features.
The EMBO Journal (2012) 31, 1308–1319. doi:10.1038/
emboj.2011.496; Published online 17 January 2012
Subject Categories: cell & tissue architecture; signal
transduction
Keywords: Hakai; phosphotyrosine; Src substrates; ubiquitin
ligases; zinc fingers
Introduction
In eukaryotic cells, phosphorylation events regulate cell
signalling by providing docking sites for protein domains,
such as the Src homology 2 (SH2) and phosphotyrosine-
binding (PTB) domains (Forman-Kay and Pawson, 1999;
Yaffe, 2002; Pawson and Nash, 2003). The SH2 was the first
signalling domain to be identified and has been extensively
characterized (Songyang et al, 1993; Forman-Kay and
Pawson, 1999; Yaffe, 2002; Pawson and Nash, 2003; Liu
et al, 2006; Filippakopoulos et al, 2009). The SH2 is a
dedicated phosphotyrosine-binding domain and plays a criti-
cal role in signal transduction, hence making it a target for
drug development (Pawson and Nash, 2003; Machida and
Mayer, 2005; Taylor et al, 2008; Kasembeli et al, 2009).
Binding specificity of SH2 domains is generally conferred by
the sequences flanking the C-terminus of the phosphotyrosine
(pTyr), and motif recognition is usually relatively inflexible.
The other major class of pTyr-binding domain is the PTB
domain. The specificity of binding to the PTB domain is
conferred typically by residues on the target that are
N-terminal to the pTyr. However, the PTB domain also
recognizes non-pTyr motifs (Forman-Kay and Pawson, 1999;
Yaffe, 2002; Pawson and Nash, 2003; Farooq and Zhou,
2004; Smith et al, 2006). Atypical phosphotyrosine-binding
domains have also been detected in PKCd and the human M2
pyruvate kinase (PKM2) (Benes et al, 2005; Christofk et al,
2008).
In 2002, Fujita et al (2002) discovered a novel ubiquitin E3
ligase protein that targeted pTyr sites on E-cadherin. The E3
ligase, Hakai, possesses three domains: a RING domain, a
short pTyr recognition sequence and a proline-rich domain
(Fujita et al, 2002). Hakai is involved in the regulation of cell
adhesion, cell migration and embryogenesis (Figueroa et al,
2009; Kaido et al, 2009; Gong et al, 2010). Among the
reported protein interactions of Hakai, its association with
and ubiquitination of E-cadherin upon Src activation is the
best characterized (Fujita et al, 2002).
Based on molecular modelling, Fujita et al (2002) assumed
the pTyr-binding domain of Hakai to be a derivative SH2
domain. Our previous experience analysing the SH2 domain
of a similar E3 ubiquitin ligase, c-Cbl (Ng et al, 2008) led us to
examine the nature of the Hakai pTyr-binding domain to
provide structural insights into its interaction with E-cadher-
in. In this study, we report that the Hakai pTyr-binding (HYB)
domain consists of a homodimer formed at a structurally
novel interface. Each monomer consists of two zinc-finger
domains: a RING domain and a minimum pTyr-binding
domain that incorporates a novel, atypical zinc coordination
motif. Both domains play key roles in dimerization. The HYB
domain is therefore composed of four zinc-binding domains
cooperating to bind pTyr residues surrounded by acidic
amino acids. Whereas the RING domain appears in other
proteins, the atypical zinc-binding domain component is a
novel protein fold that incorporates an intertwined config-
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